<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-6196 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-6196</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-6196</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-123.html">extraction-schema-123</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <p><strong>Paper ID:</strong> paper-235653942</p>
                <p><strong>Paper Title:</strong> An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease</p>
                <p><strong>Paper Abstract:</strong> The early diagnosis of Alzheimer’s disease (AD) can allow patients to take preventive measures before irreversible brain damage occurs. It can be seen from cross-sectional imaging studies of AD that the features of the lesion areas in AD patients, as observed by magnetic resonance imaging (MRI), show significant variation, and these features are distributed throughout the image space. Since the convolutional layer of the general convolutional neural network (CNN) cannot satisfactorily extract long-distance correlation in the feature space, a deep residual network (ResNet) model, based on spatial transformer networks (STN) and the non-local attention mechanism, is proposed in this study for the early diagnosis of AD. In this ResNet model, a new Mish activation function is selected in the ResNet-50 backbone to replace the Relu function, STN is introduced between the input layer and the improved ResNet-50 backbone, and a non-local attention mechanism is introduced between the fourth and the fifth stages of the improved ResNet-50 backbone. This ResNet model can extract more information from the layers by deepening the network structure through deep ResNet. The introduced STN can transform the spatial information in MRI images of Alzheimer’s patients into another space and retain the key information. The introduced non-local attention mechanism can find the relationship between the lesion areas and normal areas in the feature space. This model can solve the problem of local information loss in traditional CNN and can extract the long-distance correlation in feature space. The proposed method was validated using the ADNI (Alzheimer’s disease neuroimaging initiative) experimental dataset, and compared with several models. The experimental results show that the classification accuracy of the algorithm proposed in this study can reach 97.1%, the macro precision can reach 95.5%, the macro recall can reach 95.3%, and the macro F1 value can reach 95.4%. The proposed model is more effective than other algorithms.</p>
                <p><strong>Cost:</strong> 0.023</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e6196.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e6196.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amyloid-beta (Aβ)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid-beta peptide (Aβ, including Aβ1-42)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Extracellular peptide aggregates (notably Aβ1-42) widely implicated in AD pathology and used as a core biomarker measured in CSF and emerging blood assays.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>amyloid-beta</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Accumulation and aggregation of Aβ (especially Aβ1-42) in the brain is presented as a core pathological hallmark of AD and central to disease diagnosis; Aβ levels in CSF reflect brain amyloid pathology and are used to identify AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites that CSF Aβ1-42 is a well-validated core biomarker and that CSF Aβ1-42 showed the best diagnostic accuracy among CSF biomarkers (Michael E. et al. referenced). Structure-based Aβ blood biomarkers measured by immune infrared sensors support AD recognition with a reported sensitivity of 90% in a first-step screening (Nabers A. et al.). Combined CSF Aβ and tau measurements can improve specificity and exclude false positives (paper reports combined CSF Aβ and tau allowed exclusion of false positives with overall specificity ~97%).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Limitations noted: CSF sampling is invasive making routine use difficult; CSF Aβ1-42 specificity varies (reported specificity range 42–77% at 85% sensitivity for differentiating AD dementia from other diagnoses), indicating imperfect discrimination and potential false positives/negatives.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CSF Aβ1-42 measurement; PET amyloid imaging; blood (structure-based Aβ) assays</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>CSF assays quantify soluble Aβ1-42 concentration from lumbar puncture; PET amyloid imaging visualizes brain amyloid deposits after radiotracer injection; novel blood-based structure-sensitive assays (e.g., immune-infrared sensors) infer Aβ conformation/levels from plasma.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>CSF Aβ1-42: reported sensitivity ~85% with specificity ranging from 42% to 77% for distinguishing AD dementia from other diagnoses (Michael E. et al. cited). Structure-based Aβ blood biomarkers: reported sensitivity ~90% in first-step screening (Nabers A. et al.). Combined CSF Aβ+tau: reported overall specificity ~97% for excluding false positives (paper statement).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Preclinical and symptomatic stages (used for early/asymptomatic detection and differential diagnosis of MCI/AD).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human biomarker studies (multicenter CSF studies and blood biomarker assay reports cited).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified in detail in this paper for the cited numeric performance; references cited include clinical cohorts and AD vs other-diagnosis comparisons (Michael E.; Nabers A. et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Invasiveness of CSF sampling limits routine use; CSF biomarker specificity is variable; blood assays are emerging and require further validation and standardization before routine clinical application.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e6196.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau pathology</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tau protein (total tau T-tau and phosphorylated tau P-tau)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Intracellular neurofibrillary tangle-forming tau species (T-tau and P-tau) are core AD biomarkers and reflect neuronal injury and tau pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>tau</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Hyperphosphorylated tau accumulates as neurofibrillary tangles causing neuronal dysfunction and is a central pathological feature of AD; levels of total tau and phosphorylated tau in CSF are used to detect neuronal injury/tau pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper notes CSF T-tau and P-tau are well-validated core biomarkers with high sensitivity and specificity in identifying AD patients. Plasma tau is reported to be higher in AD independently from CSF tau and adding plasma tau to CSF tau/P-tau improves diagnostic accuracy (Fossati S. et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No direct refuting evidence discussed in this paper; limitations relate to sampling and assay variability.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CSF T-tau and P-tau assays; plasma tau assays</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>CSF assays quantify total and phosphorylated tau proteins from lumbar puncture; highly sensitive plasma assays measure tau in blood as a less invasive adjunct.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>CSF tau biomarkers are described as having high sensitivity/specificity in clinical practice; adding plasma tau to CSF tau/P-tau improves diagnostic accuracy (no single numeric AUC reported in this paper beyond the combined specificity statement of CSF Aβ+tau ~97%).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Early/asymptomatic stages and symptomatic AD; used for staging and differential diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human biomarker studies (CSF/plasma biomarker research cited).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified in detail within this paper for the tau-specific results; references include clinical cohorts and biomarker studies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>CSF collection is invasive; plasma tau assays are promising but generally presented as complementary and still require broader validation and standardization.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e6196.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>APOE ε4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Apolipoprotein E epsilon 4 allele (APOE ε4)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A common genetic risk allele that increases risk for late-onset AD and modulates biomarker profiles and disease assessment.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>APOE ε4 genotype is referenced as a factor that influences AD pathology assessment and may interact with biomarkers and sex to affect disease risk and biomarker interpretation.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites Geijselaers S. et al. who highlight the need to consider sex and the APOE ε4 genotype during assessment, implying APOE ε4's role in modulating brain insulin signaling and AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No refuting evidence discussed in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genetic testing (APOE genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Genotyping of APOE alleles from blood or saliva identifies ε4 carrier status, used as a risk stratifier rather than a standalone diagnostic test.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not quantified in this paper; APOE ε4 is described qualitatively as an important stratifier to consider in biomarker assessment.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Risk stratification across preclinical and symptomatic stages (predictive of higher conversion risk).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referential human genetic/epidemiologic studies cited.</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified in paper text for APOE-specific data.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>APOE ε4 is a risk factor but not determinative; presence or absence does not by itself diagnose AD and must be interpreted alongside biomarkers and clinical data.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e6196.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Brain insulin signaling / CSF insulin</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Brain insulin signaling and cerebrospinal fluid insulin levels</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Altered brain insulin signaling (and CSF insulin measures) is implicated as related to AD pathology and cognitive performance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>metabolic / insulin signaling</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Dysregulated insulin signaling in the brain is proposed to relate to AD pathology, potentially linking metabolic dysfunction to amyloid/tau processes and cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites Geijselaers S. et al. showing evidence of relationships between brain insulin signaling and AD pathology and associations of CSF insulin with cognitive performance and CSF AD biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No explicit counter-evidence presented in this paper; authors emphasize the need to consider sex and APOE ε4 genotype during assessment, indicating complexity.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Measurement of insulin in CSF (cerebrospinal fluid assays)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Quantification of insulin (or insulin-related markers) in CSF samples to evaluate central insulin signaling status and its association with AD biomarkers and cognition.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not numerically reported in this paper; presented as evidence of association rather than diagnostic accuracy.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Investigational biomarker across preclinical and symptomatic stages; used to study associations with cognitive performance and AD biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human CSF biomarker association studies (referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified in detail within this paper for insulin-specific results.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Association data are described but mechanistic causality is not established; confounding by sex and genotype (APOE ε4) must be considered.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e6196.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuroinflammation / Neurovascular damage</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuroinflammation and neurovascular unit damage</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Inflammatory processes and damage to the neurovascular unit are proposed mechanisms contributing to AD pathogenesis and detectable via peripheral biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>inflammation / vascular</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>AD may involve neuroinflammatory responses and injury to the neurovascular unit, contributing to neuronal damage and cognitive decline; peripheral serum biomarkers may reflect these processes.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites Abe K. et al., who suggest a serum biomarker set that indicates neuroinflammation and neurovascular unit damage as alternative pathways/mechanisms by which AD causes pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No specific refuting evidence discussed here.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Serum biomarker panels and peptidome technology</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Blood-based assays measuring panels of proteins/peptides associated with inflammation and vascular injury as potential non-invasive indicators of AD-related processes.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Abe K. et al. reported a serum biomarker set that provides rapid, non-invasive screening utility for dementia; no numerical sensitivity/specificity provided in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Investigational for MCI and AD detection/screening; presented as an alternative non-invasive screening pathway.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human serum biomarker studies cited.</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified in this paper for the serum biomarker dataset.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Findings are preliminary and presented as suggestive of alternative mechanisms; blood biomarker approaches require further validation and standardization.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e6196.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Mild Cognitive Impairment (MCI)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mild Cognitive Impairment</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An intermediate clinical state between normal cognition and Alzheimer's dementia with an elevated risk of progression to AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>prodromal stage / risk factor</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>MCI is not a cause per se but a prodromal state indicating elevated risk of conversion to AD; detecting MCI and predicting conversion are central to early intervention.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper states conversion rate from MCI to AD is significantly higher than healthy people and MCI is a major step in transition from normal to AD; ADNI dataset used includes 205 MCI samples showing applicability.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Not applicable (MCI is a clinical stage rather than a contested cause).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Cognitive assessments (MMSE, ADAS-Cog, MoCA, MBT) and neuroimaging (MRI/PET) including deep-learning MRI classification.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Standardized cognitive scales quantify cognitive deficits; structural MRI and PET detect brain atrophy/metabolic changes; deep learning on MRI slices classifies NC vs MCI vs AD.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Cognitive scales have variable performance (paper cites studies showing combinations e.g., MMSE+CVLT-LDTR can distinguish subtypes); the paper's MRI deep-learning model (proposed method) achieved 97.1% accuracy and macro F1 95.4% on ADNI multi-class NC/MCI/AD classification (N=515: NC=255, MCI=205, AD=55).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>MCI (prodromal) and early symptomatic stages; predictive of conversion risk.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human cohort data from ADNI used in the paper for model training/testing (cross-validation).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>ADNI subset: total N=515 (255 NC, 205 MCI, 55 AD); ages and MMSE/ADAS-Cog ranges reported in Table 1 of the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Cognitive tests are influenced by non-pathological subjective factors and clinician experience; imaging-based methods require preprocessing and may be limited by dataset size/generalizability; MCI is heterogeneous with variable conversion risk.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e6196.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PET imaging</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Positron Emission Tomography (PET) imaging (including 18F-FDG and amyloid PET)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Nuclear imaging technique that visualizes metabolic activity or specific molecular targets (e.g., amyloid) in the brain using radiotracers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection method)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Not a cause; PET is presented as a diagnostic imaging modality to detect lesions/metabolic change and molecular pathology (amyloid or glucose metabolism deficits).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper notes PET can detect lesions after tracer injection and FDG-PET studies have been used to identify early MCI-to-AD converters (Pagani M. et al.; Ottoy J. et al. cited).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Paper highlights PET disadvantages: poor specificity, low resolution, inaccurate anatomical localization, and high cost.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PET scanning (amyloid PET, FDG-PET)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Injection of radiotracer (amyloid-binding or glucose metabolism tracer) followed by PET acquisition to visualize molecular or metabolic abnormalities associated with AD.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>No single sensitivity/specificity provided in this paper; referenced FDG-PET studies support early identification of MCI converters but the paper emphasizes limitations in specificity and anatomical resolution.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Early/symptomatic stages and used for conversion prediction from MCI to AD in research contexts.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced human imaging cohort studies (FDG-PET and amyloid PET studies cited).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not detailed in this paper for PET-specific numeric performance (references cited contain cohort details).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>High cost, limited anatomical precision vs MRI, and lower specificity are cited as practical limitations; tracer exposure (radioactivity) is another consideration.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e6196.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MRI (conventional)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Magnetic Resonance Imaging (structural MRI)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Non-invasive imaging modality that visualizes brain structure and atrophy patterns useful for assessing AD-related neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection method)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Structural MRI detects anatomical changes, particularly regional atrophy (e.g., hippocampus), which correlate with AD progression and can help stage disease.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper states MRI clearly shows brain structure/anatomy and is conducive to measuring brain atrophy in AD; the authors used MRI slices from ADNI as primary input for their deep learning classifier.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Limitations of conventional MRI diagnosis are noted: subjective image reading by radiologists is time-consuming, labour-intensive, and can be inconsistent, motivating automated methods.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Structural MRI with manual reading or automated image analysis / deep learning classification</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>High-resolution T1-weighted MRI scans are evaluated for regional atrophy patterns; in this study 2D coronal slices were preprocessed and input to a deep ResNet-based classifier (with STN and non-local attention).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Traditional manual MRI reading: not quantified here; deep learning (proposed method) on ADNI achieved accuracy 97.1%, macro precision 95.5%, macro recall 95.3%, macro F1 95.4% (N=515, 5-fold CV). Other baseline models reported lower accuracy (ResNet50 baseline 91.3%, ResNet50+Mish 93.2%, STN+ResNet50+Mish 95.1%).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>MCI and AD (used to classify NC vs MCI vs AD and detect early neurodegeneration).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>This paper's primary study: human MRI cohort classification using machine learning (ADNI dataset).</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>ADNI subset used in paper: N=515 (255 NC, 205 MCI, 55 AD); images preprocessed and 2D slices used for training/testing with 5-fold cross-validation.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Paper notes limitations of MRI: manual reading subjectivity; their automated model used 2D slices (not full 3D), required substantial preprocessing (skull stripping, normalization), and validation is limited to ADNI dataset (generalizability to other cohorts/hospitals not shown).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e6196.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MRI + Deep Learning (ResNet-50 + STN + attention)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Improved ResNet-50 with Mish activation, Spatial Transformer Network (STN), and non-local attention for MRI-based AD diagnosis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A deep residual convolutional neural network enhanced with Mish activation, spatial transformer module, and non-local attention to improve MRI-based multi-class classification (NC/MCI/AD).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection method - algorithmic)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Not a biological cause; a proposed automated detection method that addresses long-distance feature correlations and spatial invariance in MRI slices to improve early AD diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The authors trained and validated the model on ADNI MRI slices (N=515) and report improved classification metrics compared to baseline ResNet50 and ablated variants (Mish, STN).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Not applicable as this is a methodological contribution; limitations in generalizability and reliance on 2D slices are discussed.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Deep learning classification of structural MRI slices (ResNet-50 backbone with Mish activation, STN, non-local attention)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Preprocessed 2D coronal MRI slices (224×224) fed to a ResNet50-based CNN modified with Mish activation, an upstream Spatial Transformer Network for spatial invariance, and a non-local attention block to capture long-range dependencies; trained with Adam optimizer and 5-fold CV.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Reported multi-class classification accuracy 97.1% ± 0.016 (accuracy), precision_macro 95.5% ± 0.015, recall_macro 95.3% ± 0.018, F1_macro 95.4% on ADNI subset (N=515) using 5-fold cross-validation. Baseline ResNet50 accuracy reported 91.3% (±0.035).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Normal control, MCI, and AD (multi-class classification; intended for early diagnosis including MCI detection).</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human imaging classification study using the ADNI dataset and cross-validation.</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>ADNI subset: total N=515 (255 NC, 205 MCI, 55 AD); roughly equal sex distribution; age and MMSE/ADAS-Cog ranges reported in paper Table 1.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Model trained on 2D slices rather than full 3D volumes; tested only on ADNI data (external generalizability not demonstrated); reliance on MRI preprocessing pipeline (CAT12/SPM12) introduces dependency on preprocessing quality; clinical deployment would require prospective/ multi-center validation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e6196.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF biomarker detection</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cerebrospinal fluid (CSF) biomarker assays (Aβ1-42, T-tau, P-tau)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>CSF assays measuring core AD biomarkers (Aβ1-42, total tau, phosphorylated tau) used for affirmative diagnosis and disease staging.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection method)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>CSF biomarkers reflect brain amyloid and tau pathology and neuronal injury; widely used in clinical and research settings for early and differential diagnosis of AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper states CSF Aβ1-42, T-tau, and P-tau are core biomarkers with high sensitivity and specificity and long-term stability; Michael E. et al. found CSF Aβ1-42 had best diagnostic accuracy among CSF biomarkers. Combining CSF Aβ and tau improves specificity (paper reports combined specificity ~97%).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Practical limitations: CSF collection is invasive and traumatic, limiting routine use; analytic factors like CSF storage volume can impact assay results (Delaby C. et al. cited).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Lumbar puncture followed by immunoassays / automated platforms measuring Aβ1-42, T-tau, and P-tau in CSF.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>CSF Aβ1-42: sensitivity reported ~85% with specificity 42–77% for differentiating AD dementia from other diagnoses (Michael E. et al.). Combined CSF Aβ+tau: reported overall specificity ~97% for excluding false positives (paper statement).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Early/asymptomatic stages and symptomatic AD; used for staging and monitoring progression.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Large-scale multicenter human CSF biomarker studies referenced.</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited studies include AD and other diagnostic groups; this paper does not reanalyze raw CSF cohorts but references published cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Invasive sample collection reduces suitability for routine screening; pre-analytic variables (storage volume, handling) can affect results; specificity and sensitivity vary across cohorts and comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e6196.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Blood / Plasma biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Blood-based biomarkers (plasma tau, structure-based Aβ/tau assays, proteomic/peptidome panels)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Non-invasive peripheral assays (plasma tau, structure-sensitive Aβ/tau, serum peptidome panels) under investigation to screen for or complement CSF/PET biomarkers in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection method)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Blood-based assays measure AD-associated proteins (tau, Aβ conformations) or panels of peptides/proteins; intended as minimally invasive screening tools or adjuncts to CSF/PET diagnostics.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites multiple studies: Fossati S. et al. report plasma tau is higher in AD and improves diagnostic accuracy when combined with CSF tau; Nabers A. et al. used immune infrared sensors for structure-based Aβ/tau with blood biomarkers supporting AD recognition with 90% sensitivity in a first-step screening; Abe K. et al. reported a serum biomarker set detecting MCI/AD with rapid, non-invasive utility.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Paper frames these as promising advances but acknowledges they are emerging and not yet routine; no large-scale standardization data provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Immunoassays and structure-sensitive biophysical assays on plasma/serum; peptidome/proteomic panels measured by mass spectrometry or sensor technologies.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Structure-based Aβ blood biomarkers: reported sensitivity ~90% in first-step screening (Nabers A. et al.). Plasma tau: reported to complement CSF tau and improve diagnostic accuracy (no single numeric AUC provided in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Investigational for screening and early detection including preclinical and MCI stages.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Human biomarker studies; exploratory and validation cohorts cited in references.</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified in detail here; referenced studies used clinical cohorts and biomarker assay validation sets.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Blood biomarkers are promising but require larger-scale validation, harmonization of assays, and standardization across labs before widespread clinical adoption.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e6196.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cognitive assessments (MMSE, MoCA, ADAS-Cog, CDT, MBT)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Standardized cognitive screening and assessment tools (Mini-Mental State Examination, Montreal Cognitive Assessment, ADAS-Cog, Clock Drawing Test, Memory Binding Test)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Brief neuropsychological tests used clinically to screen and quantify cognitive impairment, commonly applied to detect MCI and AD-related cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection method)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Clinical cognitive tests measure global or domain-specific cognitive performance (memory, executive function, visuospatial skills) and are used for screening and longitudinal tracking of cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites multiple studies: Brodaty et al. report clock drawing test effective with low false-negative/positive rates in clinical populations; Pozueta et al. show combinations (MMSE + CVLT-LDTR) can distinguish early PR-AD and S-MCI; Zainal et al. note ADAS-Cog suitable for an Asian cohort; other citations discuss MMSE sensitivity to disease course and limitations of MoCA interpretation.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Paper emphasizes cognitive tests lack objective biological evidence and are susceptible to non-pathological subjective influences and clinician variability, leading to possible misdiagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Paper-and-pencil or computerized neuropsychological assessments administered by clinicians.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Performance varies by test and cohort; qualitative statements include that clock drawing test has low false-negative/positive in certain clinical populations, and combined tests can improve discrimination; no uniform numeric sensitivity/specificity reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Primarily MCI and symptomatic AD; used for screening and tracking cognitive trajectories.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical neuropsychological studies and validation papers cited.</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Various cohorts as cited in referenced studies; not pooled or numerically summarized within this paper beyond commentary.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Subjectivity, influence of education/culture/language, and dependence on examiner expertise limit reliability; some tests show unclear clinical significance for small score changes (e.g., MOCA).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6196.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e6196.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Combined biomarker strategies</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Combined biomarker approaches (CSF, imaging, cognitive, blood biomarker combinations)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multimodal strategies combining CSF biomarkers, imaging (MRI/PET), cognitive tests and blood biomarkers to improve prediction of MCI-to-AD conversion and diagnostic accuracy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>n/a (detection strategy)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Combining different biomarker modalities leverages complementary information (molecular pathology, neurodegeneration, cognition) to enhance early detection and prediction of progression.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Paper cites Zhao A. et al. and other reviews noting increased prediction value of biomarker combinations for conversion from MCI to AD and improved diagnostic performance when plasma biomarkers are added to CSF measures; the paper itself underscores the potential of combining genetic susceptibility with pattern recognition as future work.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Not directly refuted; practical challenges include invasiveness (CSF), cost (PET), assay harmonization, and need for integrated analytical frameworks.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Multimodal diagnostics using combinations of CSF assays, blood assays, structural/functional imaging, and cognitive testing; machine learning integration is proposed.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Integrative use of molecular (CSF/plasma), imaging (MRI/PET), and clinical/cognitive data combined via statistical or machine-learning models to predict diagnosis or conversion.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper cites that biomarker combinations increase predictive value (Zhao et al. referenced) and that plasma+CSF combinations can improve diagnostic accuracy; no single pooled numeric performance metric is provided in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Preclinical, MCI, and early symptomatic stages for predicting conversion and improving diagnostic specificity/sensitivity.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Referenced human cohort and biomarker combination studies; the paper suggests future combination with genetic detection and pattern recognition.</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not summarized in this paper; referenced studies include MCI and AD cohorts used for conversion prediction analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Combining modalities raises logistical/cost issues (PET, CSF), requires harmonization across assays and imaging protocols, and needs robust validation in multi-center cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease', 'publication_date_yy_mm': '2021-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine <em>(Rating: 2)</em></li>
                <li>Peripheral Biomarkers for Alzheimer's Disease: Update and Progress <em>(Rating: 2)</em></li>
                <li>Blood tests to screen for Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study <em>(Rating: 2)</em></li>
                <li>Aβ and tau structure-based biomarkers for a blood-and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease <em>(Rating: 2)</em></li>
                <li>Early identification of MCI converting to AD: A FDG PET study <em>(Rating: 1)</em></li>
                <li>Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia <em>(Rating: 2)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-6196",
    "paper_id": "paper-235653942",
    "extraction_schema_id": "extraction-schema-123",
    "extracted_data": [
        {
            "name_short": "Amyloid-beta (Aβ)",
            "name_full": "Amyloid-beta peptide (Aβ, including Aβ1-42)",
            "brief_description": "Extracellular peptide aggregates (notably Aβ1-42) widely implicated in AD pathology and used as a core biomarker measured in CSF and emerging blood assays.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "amyloid-beta",
            "cause_description": "Accumulation and aggregation of Aβ (especially Aβ1-42) in the brain is presented as a core pathological hallmark of AD and central to disease diagnosis; Aβ levels in CSF reflect brain amyloid pathology and are used to identify AD pathology.",
            "evidence_for_cause": "Paper cites that CSF Aβ1-42 is a well-validated core biomarker and that CSF Aβ1-42 showed the best diagnostic accuracy among CSF biomarkers (Michael E. et al. referenced). Structure-based Aβ blood biomarkers measured by immune infrared sensors support AD recognition with a reported sensitivity of 90% in a first-step screening (Nabers A. et al.). Combined CSF Aβ and tau measurements can improve specificity and exclude false positives (paper reports combined CSF Aβ and tau allowed exclusion of false positives with overall specificity ~97%).",
            "evidence_against_cause": "Limitations noted: CSF sampling is invasive making routine use difficult; CSF Aβ1-42 specificity varies (reported specificity range 42–77% at 85% sensitivity for differentiating AD dementia from other diagnoses), indicating imperfect discrimination and potential false positives/negatives.",
            "detection_method": "CSF Aβ1-42 measurement; PET amyloid imaging; blood (structure-based Aβ) assays",
            "detection_method_description": "CSF assays quantify soluble Aβ1-42 concentration from lumbar puncture; PET amyloid imaging visualizes brain amyloid deposits after radiotracer injection; novel blood-based structure-sensitive assays (e.g., immune-infrared sensors) infer Aβ conformation/levels from plasma.",
            "detection_performance": "CSF Aβ1-42: reported sensitivity ~85% with specificity ranging from 42% to 77% for distinguishing AD dementia from other diagnoses (Michael E. et al. cited). Structure-based Aβ blood biomarkers: reported sensitivity ~90% in first-step screening (Nabers A. et al.). Combined CSF Aβ+tau: reported overall specificity ~97% for excluding false positives (paper statement).",
            "disease_stage_detected": "Preclinical and symptomatic stages (used for early/asymptomatic detection and differential diagnosis of MCI/AD).",
            "study_type": "Human biomarker studies (multicenter CSF studies and blood biomarker assay reports cited).",
            "study_population": "Not specified in detail in this paper for the cited numeric performance; references cited include clinical cohorts and AD vs other-diagnosis comparisons (Michael E.; Nabers A. et al.).",
            "limitations_or_counterpoints": "Invasiveness of CSF sampling limits routine use; CSF biomarker specificity is variable; blood assays are emerging and require further validation and standardization before routine clinical application.",
            "uuid": "e6196.0",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "Tau pathology",
            "name_full": "Tau protein (total tau T-tau and phosphorylated tau P-tau)",
            "brief_description": "Intracellular neurofibrillary tangle-forming tau species (T-tau and P-tau) are core AD biomarkers and reflect neuronal injury and tau pathology.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "tau",
            "cause_description": "Hyperphosphorylated tau accumulates as neurofibrillary tangles causing neuronal dysfunction and is a central pathological feature of AD; levels of total tau and phosphorylated tau in CSF are used to detect neuronal injury/tau pathology.",
            "evidence_for_cause": "Paper notes CSF T-tau and P-tau are well-validated core biomarkers with high sensitivity and specificity in identifying AD patients. Plasma tau is reported to be higher in AD independently from CSF tau and adding plasma tau to CSF tau/P-tau improves diagnostic accuracy (Fossati S. et al.).",
            "evidence_against_cause": "No direct refuting evidence discussed in this paper; limitations relate to sampling and assay variability.",
            "detection_method": "CSF T-tau and P-tau assays; plasma tau assays",
            "detection_method_description": "CSF assays quantify total and phosphorylated tau proteins from lumbar puncture; highly sensitive plasma assays measure tau in blood as a less invasive adjunct.",
            "detection_performance": "CSF tau biomarkers are described as having high sensitivity/specificity in clinical practice; adding plasma tau to CSF tau/P-tau improves diagnostic accuracy (no single numeric AUC reported in this paper beyond the combined specificity statement of CSF Aβ+tau ~97%).",
            "disease_stage_detected": "Early/asymptomatic stages and symptomatic AD; used for staging and differential diagnosis.",
            "study_type": "Human biomarker studies (CSF/plasma biomarker research cited).",
            "study_population": "Not specified in detail within this paper for the tau-specific results; references include clinical cohorts and biomarker studies.",
            "limitations_or_counterpoints": "CSF collection is invasive; plasma tau assays are promising but generally presented as complementary and still require broader validation and standardization.",
            "uuid": "e6196.1",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "APOE ε4",
            "name_full": "Apolipoprotein E epsilon 4 allele (APOE ε4)",
            "brief_description": "A common genetic risk allele that increases risk for late-onset AD and modulates biomarker profiles and disease assessment.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "genetic",
            "cause_description": "APOE ε4 genotype is referenced as a factor that influences AD pathology assessment and may interact with biomarkers and sex to affect disease risk and biomarker interpretation.",
            "evidence_for_cause": "Paper cites Geijselaers S. et al. who highlight the need to consider sex and the APOE ε4 genotype during assessment, implying APOE ε4's role in modulating brain insulin signaling and AD pathology.",
            "evidence_against_cause": "No refuting evidence discussed in this paper.",
            "detection_method": "Genetic testing (APOE genotyping)",
            "detection_method_description": "Genotyping of APOE alleles from blood or saliva identifies ε4 carrier status, used as a risk stratifier rather than a standalone diagnostic test.",
            "detection_performance": "Not quantified in this paper; APOE ε4 is described qualitatively as an important stratifier to consider in biomarker assessment.",
            "disease_stage_detected": "Risk stratification across preclinical and symptomatic stages (predictive of higher conversion risk).",
            "study_type": "Referential human genetic/epidemiologic studies cited.",
            "study_population": "Not specified in paper text for APOE-specific data.",
            "limitations_or_counterpoints": "APOE ε4 is a risk factor but not determinative; presence or absence does not by itself diagnose AD and must be interpreted alongside biomarkers and clinical data.",
            "uuid": "e6196.2",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "Brain insulin signaling / CSF insulin",
            "name_full": "Brain insulin signaling and cerebrospinal fluid insulin levels",
            "brief_description": "Altered brain insulin signaling (and CSF insulin measures) is implicated as related to AD pathology and cognitive performance.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "metabolic / insulin signaling",
            "cause_description": "Dysregulated insulin signaling in the brain is proposed to relate to AD pathology, potentially linking metabolic dysfunction to amyloid/tau processes and cognitive impairment.",
            "evidence_for_cause": "Paper cites Geijselaers S. et al. showing evidence of relationships between brain insulin signaling and AD pathology and associations of CSF insulin with cognitive performance and CSF AD biomarkers.",
            "evidence_against_cause": "No explicit counter-evidence presented in this paper; authors emphasize the need to consider sex and APOE ε4 genotype during assessment, indicating complexity.",
            "detection_method": "Measurement of insulin in CSF (cerebrospinal fluid assays)",
            "detection_method_description": "Quantification of insulin (or insulin-related markers) in CSF samples to evaluate central insulin signaling status and its association with AD biomarkers and cognition.",
            "detection_performance": "Not numerically reported in this paper; presented as evidence of association rather than diagnostic accuracy.",
            "disease_stage_detected": "Investigational biomarker across preclinical and symptomatic stages; used to study associations with cognitive performance and AD biomarkers.",
            "study_type": "Human CSF biomarker association studies (referenced).",
            "study_population": "Not specified in detail within this paper for insulin-specific results.",
            "limitations_or_counterpoints": "Association data are described but mechanistic causality is not established; confounding by sex and genotype (APOE ε4) must be considered.",
            "uuid": "e6196.3",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "Neuroinflammation / Neurovascular damage",
            "name_full": "Neuroinflammation and neurovascular unit damage",
            "brief_description": "Inflammatory processes and damage to the neurovascular unit are proposed mechanisms contributing to AD pathogenesis and detectable via peripheral biomarkers.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "inflammation / vascular",
            "cause_description": "AD may involve neuroinflammatory responses and injury to the neurovascular unit, contributing to neuronal damage and cognitive decline; peripheral serum biomarkers may reflect these processes.",
            "evidence_for_cause": "Paper cites Abe K. et al., who suggest a serum biomarker set that indicates neuroinflammation and neurovascular unit damage as alternative pathways/mechanisms by which AD causes pathology.",
            "evidence_against_cause": "No specific refuting evidence discussed here.",
            "detection_method": "Serum biomarker panels and peptidome technology",
            "detection_method_description": "Blood-based assays measuring panels of proteins/peptides associated with inflammation and vascular injury as potential non-invasive indicators of AD-related processes.",
            "detection_performance": "Abe K. et al. reported a serum biomarker set that provides rapid, non-invasive screening utility for dementia; no numerical sensitivity/specificity provided in this paper.",
            "disease_stage_detected": "Investigational for MCI and AD detection/screening; presented as an alternative non-invasive screening pathway.",
            "study_type": "Human serum biomarker studies cited.",
            "study_population": "Not specified in this paper for the serum biomarker dataset.",
            "limitations_or_counterpoints": "Findings are preliminary and presented as suggestive of alternative mechanisms; blood biomarker approaches require further validation and standardization.",
            "uuid": "e6196.4",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "Mild Cognitive Impairment (MCI)",
            "name_full": "Mild Cognitive Impairment",
            "brief_description": "An intermediate clinical state between normal cognition and Alzheimer's dementia with an elevated risk of progression to AD.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "use",
            "cause_type": "prodromal stage / risk factor",
            "cause_description": "MCI is not a cause per se but a prodromal state indicating elevated risk of conversion to AD; detecting MCI and predicting conversion are central to early intervention.",
            "evidence_for_cause": "Paper states conversion rate from MCI to AD is significantly higher than healthy people and MCI is a major step in transition from normal to AD; ADNI dataset used includes 205 MCI samples showing applicability.",
            "evidence_against_cause": "Not applicable (MCI is a clinical stage rather than a contested cause).",
            "detection_method": "Cognitive assessments (MMSE, ADAS-Cog, MoCA, MBT) and neuroimaging (MRI/PET) including deep-learning MRI classification.",
            "detection_method_description": "Standardized cognitive scales quantify cognitive deficits; structural MRI and PET detect brain atrophy/metabolic changes; deep learning on MRI slices classifies NC vs MCI vs AD.",
            "detection_performance": "Cognitive scales have variable performance (paper cites studies showing combinations e.g., MMSE+CVLT-LDTR can distinguish subtypes); the paper's MRI deep-learning model (proposed method) achieved 97.1% accuracy and macro F1 95.4% on ADNI multi-class NC/MCI/AD classification (N=515: NC=255, MCI=205, AD=55).",
            "disease_stage_detected": "MCI (prodromal) and early symptomatic stages; predictive of conversion risk.",
            "study_type": "Human cohort data from ADNI used in the paper for model training/testing (cross-validation).",
            "study_population": "ADNI subset: total N=515 (255 NC, 205 MCI, 55 AD); ages and MMSE/ADAS-Cog ranges reported in Table 1 of the paper.",
            "limitations_or_counterpoints": "Cognitive tests are influenced by non-pathological subjective factors and clinician experience; imaging-based methods require preprocessing and may be limited by dataset size/generalizability; MCI is heterogeneous with variable conversion risk.",
            "uuid": "e6196.5",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "PET imaging",
            "name_full": "Positron Emission Tomography (PET) imaging (including 18F-FDG and amyloid PET)",
            "brief_description": "Nuclear imaging technique that visualizes metabolic activity or specific molecular targets (e.g., amyloid) in the brain using radiotracers.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "n/a (detection method)",
            "cause_description": "Not a cause; PET is presented as a diagnostic imaging modality to detect lesions/metabolic change and molecular pathology (amyloid or glucose metabolism deficits).",
            "evidence_for_cause": "Paper notes PET can detect lesions after tracer injection and FDG-PET studies have been used to identify early MCI-to-AD converters (Pagani M. et al.; Ottoy J. et al. cited).",
            "evidence_against_cause": "Paper highlights PET disadvantages: poor specificity, low resolution, inaccurate anatomical localization, and high cost.",
            "detection_method": "PET scanning (amyloid PET, FDG-PET)",
            "detection_method_description": "Injection of radiotracer (amyloid-binding or glucose metabolism tracer) followed by PET acquisition to visualize molecular or metabolic abnormalities associated with AD.",
            "detection_performance": "No single sensitivity/specificity provided in this paper; referenced FDG-PET studies support early identification of MCI converters but the paper emphasizes limitations in specificity and anatomical resolution.",
            "disease_stage_detected": "Early/symptomatic stages and used for conversion prediction from MCI to AD in research contexts.",
            "study_type": "Referenced human imaging cohort studies (FDG-PET and amyloid PET studies cited).",
            "study_population": "Not detailed in this paper for PET-specific numeric performance (references cited contain cohort details).",
            "limitations_or_counterpoints": "High cost, limited anatomical precision vs MRI, and lower specificity are cited as practical limitations; tracer exposure (radioactivity) is another consideration.",
            "uuid": "e6196.6",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "MRI (conventional)",
            "name_full": "Magnetic Resonance Imaging (structural MRI)",
            "brief_description": "Non-invasive imaging modality that visualizes brain structure and atrophy patterns useful for assessing AD-related neurodegeneration.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "use",
            "cause_type": "n/a (detection method)",
            "cause_description": "Structural MRI detects anatomical changes, particularly regional atrophy (e.g., hippocampus), which correlate with AD progression and can help stage disease.",
            "evidence_for_cause": "Paper states MRI clearly shows brain structure/anatomy and is conducive to measuring brain atrophy in AD; the authors used MRI slices from ADNI as primary input for their deep learning classifier.",
            "evidence_against_cause": "Limitations of conventional MRI diagnosis are noted: subjective image reading by radiologists is time-consuming, labour-intensive, and can be inconsistent, motivating automated methods.",
            "detection_method": "Structural MRI with manual reading or automated image analysis / deep learning classification",
            "detection_method_description": "High-resolution T1-weighted MRI scans are evaluated for regional atrophy patterns; in this study 2D coronal slices were preprocessed and input to a deep ResNet-based classifier (with STN and non-local attention).",
            "detection_performance": "Traditional manual MRI reading: not quantified here; deep learning (proposed method) on ADNI achieved accuracy 97.1%, macro precision 95.5%, macro recall 95.3%, macro F1 95.4% (N=515, 5-fold CV). Other baseline models reported lower accuracy (ResNet50 baseline 91.3%, ResNet50+Mish 93.2%, STN+ResNet50+Mish 95.1%).",
            "disease_stage_detected": "MCI and AD (used to classify NC vs MCI vs AD and detect early neurodegeneration).",
            "study_type": "This paper's primary study: human MRI cohort classification using machine learning (ADNI dataset).",
            "study_population": "ADNI subset used in paper: N=515 (255 NC, 205 MCI, 55 AD); images preprocessed and 2D slices used for training/testing with 5-fold cross-validation.",
            "limitations_or_counterpoints": "Paper notes limitations of MRI: manual reading subjectivity; their automated model used 2D slices (not full 3D), required substantial preprocessing (skull stripping, normalization), and validation is limited to ADNI dataset (generalizability to other cohorts/hospitals not shown).",
            "uuid": "e6196.7",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "MRI + Deep Learning (ResNet-50 + STN + attention)",
            "name_full": "Improved ResNet-50 with Mish activation, Spatial Transformer Network (STN), and non-local attention for MRI-based AD diagnosis",
            "brief_description": "A deep residual convolutional neural network enhanced with Mish activation, spatial transformer module, and non-local attention to improve MRI-based multi-class classification (NC/MCI/AD).",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "use",
            "cause_type": "n/a (detection method - algorithmic)",
            "cause_description": "Not a biological cause; a proposed automated detection method that addresses long-distance feature correlations and spatial invariance in MRI slices to improve early AD diagnosis.",
            "evidence_for_cause": "The authors trained and validated the model on ADNI MRI slices (N=515) and report improved classification metrics compared to baseline ResNet50 and ablated variants (Mish, STN).",
            "evidence_against_cause": "Not applicable as this is a methodological contribution; limitations in generalizability and reliance on 2D slices are discussed.",
            "detection_method": "Deep learning classification of structural MRI slices (ResNet-50 backbone with Mish activation, STN, non-local attention)",
            "detection_method_description": "Preprocessed 2D coronal MRI slices (224×224) fed to a ResNet50-based CNN modified with Mish activation, an upstream Spatial Transformer Network for spatial invariance, and a non-local attention block to capture long-range dependencies; trained with Adam optimizer and 5-fold CV.",
            "detection_performance": "Reported multi-class classification accuracy 97.1% ± 0.016 (accuracy), precision_macro 95.5% ± 0.015, recall_macro 95.3% ± 0.018, F1_macro 95.4% on ADNI subset (N=515) using 5-fold cross-validation. Baseline ResNet50 accuracy reported 91.3% (±0.035).",
            "disease_stage_detected": "Normal control, MCI, and AD (multi-class classification; intended for early diagnosis including MCI detection).",
            "study_type": "Human imaging classification study using the ADNI dataset and cross-validation.",
            "study_population": "ADNI subset: total N=515 (255 NC, 205 MCI, 55 AD); roughly equal sex distribution; age and MMSE/ADAS-Cog ranges reported in paper Table 1.",
            "limitations_or_counterpoints": "Model trained on 2D slices rather than full 3D volumes; tested only on ADNI data (external generalizability not demonstrated); reliance on MRI preprocessing pipeline (CAT12/SPM12) introduces dependency on preprocessing quality; clinical deployment would require prospective/ multi-center validation.",
            "uuid": "e6196.8",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "CSF biomarker detection",
            "name_full": "Cerebrospinal fluid (CSF) biomarker assays (Aβ1-42, T-tau, P-tau)",
            "brief_description": "CSF assays measuring core AD biomarkers (Aβ1-42, total tau, phosphorylated tau) used for affirmative diagnosis and disease staging.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "n/a (detection method)",
            "cause_description": "CSF biomarkers reflect brain amyloid and tau pathology and neuronal injury; widely used in clinical and research settings for early and differential diagnosis of AD.",
            "evidence_for_cause": "Paper states CSF Aβ1-42, T-tau, and P-tau are core biomarkers with high sensitivity and specificity and long-term stability; Michael E. et al. found CSF Aβ1-42 had best diagnostic accuracy among CSF biomarkers. Combining CSF Aβ and tau improves specificity (paper reports combined specificity ~97%).",
            "evidence_against_cause": "Practical limitations: CSF collection is invasive and traumatic, limiting routine use; analytic factors like CSF storage volume can impact assay results (Delaby C. et al. cited).",
            "detection_method": "Lumbar puncture followed by immunoassays / automated platforms measuring Aβ1-42, T-tau, and P-tau in CSF.",
            "detection_performance": "CSF Aβ1-42: sensitivity reported ~85% with specificity 42–77% for differentiating AD dementia from other diagnoses (Michael E. et al.). Combined CSF Aβ+tau: reported overall specificity ~97% for excluding false positives (paper statement).",
            "disease_stage_detected": "Early/asymptomatic stages and symptomatic AD; used for staging and monitoring progression.",
            "study_type": "Large-scale multicenter human CSF biomarker studies referenced.",
            "study_population": "Cited studies include AD and other diagnostic groups; this paper does not reanalyze raw CSF cohorts but references published cohorts.",
            "limitations_or_counterpoints": "Invasive sample collection reduces suitability for routine screening; pre-analytic variables (storage volume, handling) can affect results; specificity and sensitivity vary across cohorts and comparisons.",
            "uuid": "e6196.9",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "Blood / Plasma biomarkers",
            "name_full": "Blood-based biomarkers (plasma tau, structure-based Aβ/tau assays, proteomic/peptidome panels)",
            "brief_description": "Non-invasive peripheral assays (plasma tau, structure-sensitive Aβ/tau, serum peptidome panels) under investigation to screen for or complement CSF/PET biomarkers in AD.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "n/a (detection method)",
            "cause_description": "Blood-based assays measure AD-associated proteins (tau, Aβ conformations) or panels of peptides/proteins; intended as minimally invasive screening tools or adjuncts to CSF/PET diagnostics.",
            "evidence_for_cause": "Paper cites multiple studies: Fossati S. et al. report plasma tau is higher in AD and improves diagnostic accuracy when combined with CSF tau; Nabers A. et al. used immune infrared sensors for structure-based Aβ/tau with blood biomarkers supporting AD recognition with 90% sensitivity in a first-step screening; Abe K. et al. reported a serum biomarker set detecting MCI/AD with rapid, non-invasive utility.",
            "evidence_against_cause": "Paper frames these as promising advances but acknowledges they are emerging and not yet routine; no large-scale standardization data provided here.",
            "detection_method": "Immunoassays and structure-sensitive biophysical assays on plasma/serum; peptidome/proteomic panels measured by mass spectrometry or sensor technologies.",
            "detection_performance": "Structure-based Aβ blood biomarkers: reported sensitivity ~90% in first-step screening (Nabers A. et al.). Plasma tau: reported to complement CSF tau and improve diagnostic accuracy (no single numeric AUC provided in this paper).",
            "disease_stage_detected": "Investigational for screening and early detection including preclinical and MCI stages.",
            "study_type": "Human biomarker studies; exploratory and validation cohorts cited in references.",
            "study_population": "Not specified in detail here; referenced studies used clinical cohorts and biomarker assay validation sets.",
            "limitations_or_counterpoints": "Blood biomarkers are promising but require larger-scale validation, harmonization of assays, and standardization across labs before widespread clinical adoption.",
            "uuid": "e6196.10",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "Cognitive assessments (MMSE, MoCA, ADAS-Cog, CDT, MBT)",
            "name_full": "Standardized cognitive screening and assessment tools (Mini-Mental State Examination, Montreal Cognitive Assessment, ADAS-Cog, Clock Drawing Test, Memory Binding Test)",
            "brief_description": "Brief neuropsychological tests used clinically to screen and quantify cognitive impairment, commonly applied to detect MCI and AD-related cognitive decline.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "n/a (detection method)",
            "cause_description": "Clinical cognitive tests measure global or domain-specific cognitive performance (memory, executive function, visuospatial skills) and are used for screening and longitudinal tracking of cognitive decline.",
            "evidence_for_cause": "Paper cites multiple studies: Brodaty et al. report clock drawing test effective with low false-negative/positive rates in clinical populations; Pozueta et al. show combinations (MMSE + CVLT-LDTR) can distinguish early PR-AD and S-MCI; Zainal et al. note ADAS-Cog suitable for an Asian cohort; other citations discuss MMSE sensitivity to disease course and limitations of MoCA interpretation.",
            "evidence_against_cause": "Paper emphasizes cognitive tests lack objective biological evidence and are susceptible to non-pathological subjective influences and clinician variability, leading to possible misdiagnosis.",
            "detection_method": "Paper-and-pencil or computerized neuropsychological assessments administered by clinicians.",
            "detection_performance": "Performance varies by test and cohort; qualitative statements include that clock drawing test has low false-negative/positive in certain clinical populations, and combined tests can improve discrimination; no uniform numeric sensitivity/specificity reported in this paper.",
            "disease_stage_detected": "Primarily MCI and symptomatic AD; used for screening and tracking cognitive trajectories.",
            "study_type": "Clinical neuropsychological studies and validation papers cited.",
            "study_population": "Various cohorts as cited in referenced studies; not pooled or numerically summarized within this paper beyond commentary.",
            "limitations_or_counterpoints": "Subjectivity, influence of education/culture/language, and dependence on examiner expertise limit reliability; some tests show unclear clinical significance for small score changes (e.g., MOCA).",
            "uuid": "e6196.11",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        },
        {
            "name_short": "Combined biomarker strategies",
            "name_full": "Combined biomarker approaches (CSF, imaging, cognitive, blood biomarker combinations)",
            "brief_description": "Multimodal strategies combining CSF biomarkers, imaging (MRI/PET), cognitive tests and blood biomarkers to improve prediction of MCI-to-AD conversion and diagnostic accuracy.",
            "citation_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "n/a (detection strategy)",
            "cause_description": "Combining different biomarker modalities leverages complementary information (molecular pathology, neurodegeneration, cognition) to enhance early detection and prediction of progression.",
            "evidence_for_cause": "Paper cites Zhao A. et al. and other reviews noting increased prediction value of biomarker combinations for conversion from MCI to AD and improved diagnostic performance when plasma biomarkers are added to CSF measures; the paper itself underscores the potential of combining genetic susceptibility with pattern recognition as future work.",
            "evidence_against_cause": "Not directly refuted; practical challenges include invasiveness (CSF), cost (PET), assay harmonization, and need for integrated analytical frameworks.",
            "detection_method": "Multimodal diagnostics using combinations of CSF assays, blood assays, structural/functional imaging, and cognitive testing; machine learning integration is proposed.",
            "detection_method_description": "Integrative use of molecular (CSF/plasma), imaging (MRI/PET), and clinical/cognitive data combined via statistical or machine-learning models to predict diagnosis or conversion.",
            "detection_performance": "Paper cites that biomarker combinations increase predictive value (Zhao et al. referenced) and that plasma+CSF combinations can improve diagnostic accuracy; no single pooled numeric performance metric is provided in this paper.",
            "disease_stage_detected": "Preclinical, MCI, and early symptomatic stages for predicting conversion and improving diagnostic specificity/sensitivity.",
            "study_type": "Referenced human cohort and biomarker combination studies; the paper suggests future combination with genetic detection and pattern recognition.",
            "study_population": "Not summarized in this paper; referenced studies include MCI and AD cohorts used for conversion prediction analyses.",
            "limitations_or_counterpoints": "Combining modalities raises logistical/cost issues (PET, CSF), requires harmonization across assays and imaging protocols, and needs robust validation in multi-center cohorts.",
            "uuid": "e6196.12",
            "source_info": {
                "paper_title": "An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer’s Disease",
                "publication_date_yy_mm": "2021-06"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine",
            "rating": 2,
            "sanitized_title": "biomarkers_for_alzheimers_disease_ad_and_the_application_of_precision_medicine"
        },
        {
            "paper_title": "Peripheral Biomarkers for Alzheimer's Disease: Update and Progress",
            "rating": 2,
            "sanitized_title": "peripheral_biomarkers_for_alzheimers_disease_update_and_progress"
        },
        {
            "paper_title": "Blood tests to screen for Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "blood_tests_to_screen_for_alzheimers_disease"
        },
        {
            "paper_title": "CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study",
            "rating": 2,
            "sanitized_title": "csf_biomarkers_for_the_differential_diagnosis_of_alzheimers_disease_a_largescale_international_multicenter_study"
        },
        {
            "paper_title": "Aβ and tau structure-based biomarkers for a blood-and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "aβ_and_tau_structurebased_biomarkers_for_a_bloodand_csfbased_twostep_recruitment_strategy_to_identify_patients_with_dementia_due_to_alzheimers_disease"
        },
        {
            "paper_title": "Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease",
            "rating": 2,
            "sanitized_title": "association_of_cerebrospinal_fluid_csf_insulin_with_cognitive_performance_and_csf_biomarkers_of_alzheimers_disease"
        },
        {
            "paper_title": "Early identification of MCI converting to AD: A FDG PET study",
            "rating": 1,
            "sanitized_title": "early_identification_of_mci_converting_to_ad_a_fdg_pet_study"
        },
        {
            "paper_title": "Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia",
            "rating": 2,
            "sanitized_title": "increased_prediction_value_of_biomarker_combinations_for_the_conversion_of_mild_cognitive_impairment_to_alzheimers_dementia"
        }
    ],
    "cost": 0.023403,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease
Published: 18 June 2021</p>
<p>Haijing Sun 
College of Information Science and Engineering
Northeastern University
110819ShenyangChina</p>
<p>College of Information Engineering
Shenyang University
110044ShenyangChina</p>
<p>Anna Wang wanganna@mail.neu.edu.cn 
College of Information Science and Engineering
Northeastern University
110819ShenyangChina</p>
<p>Wenhui Wang wenhuiwang@stumail.neu.edu.cnw.w. 
Chen Liu liuchenne@gmail.comc.l. 
College of Information Science and Engineering
Northeastern University
110819ShenyangChina</p>
<p>Alan Jović 
College of Information Science and Engineering
Northeastern University
110819ShenyangChina</p>
<p>An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease
Published: 18 June 202110.3390/s21124182Received: 21 May 2021 Accepted: 16 June 2021sensors Article Citation: Sun, H.; Wang, A.; Wang, W.; Liu, C. An Improved Deep Residual Network Prediction Model for the Early Diagnosis of Alzheimer's Disease. Sensors 2021, 21, 4182. https://doi.org/10.3390/ s21124182 Academic Editor: Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil-iations. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). * Correspondence:residual networkMishspatial transformer networksnon-local attention mechanismAlzheimer's disease
The early diagnosis of Alzheimer's disease (AD) can allow patients to take preventive measures before irreversible brain damage occurs. It can be seen from cross-sectional imaging studies of AD that the features of the lesion areas in AD patients, as observed by magnetic resonance imaging (MRI), show significant variation, and these features are distributed throughout the image space. Since the convolutional layer of the general convolutional neural network (CNN) cannot satisfactorily extract long-distance correlation in the feature space, a deep residual network (ResNet) model, based on spatial transformer networks (STN) and the non-local attention mechanism, is proposed in this study for the early diagnosis of AD. In this ResNet model, a new Mish activation function is selected in the ResNet-50 backbone to replace the Relu function, STN is introduced between the input layer and the improved ResNet-50 backbone, and a non-local attention mechanism is introduced between the fourth and the fifth stages of the improved ResNet-50 backbone. This ResNet model can extract more information from the layers by deepening the network structure through deep ResNet. The introduced STN can transform the spatial information in MRI images of Alzheimer's patients into another space and retain the key information. The introduced non-local attention mechanism can find the relationship between the lesion areas and normal areas in the feature space. This model can solve the problem of local information loss in traditional CNN and can extract the long-distance correlation in feature space. The proposed method was validated using the ADNI (Alzheimer's disease neuroimaging initiative) experimental dataset, and compared with several models. The experimental results show that the classification accuracy of the algorithm proposed in this study can reach 97.1%, the macro precision can reach 95.5%, the macro recall can reach 95.3%, and the macro F1 value can reach 95.4%. The proposed model is more effective than other algorithms. Sensors 2021, 21, 4182. https://doi.org/10.3390/s21124182 https://www.mdpi.com/journal/sensors Sensors 2021, 21, 4182 2 of 15brain damage takes place. Therefore, the early and accurate diagnosis of AD has important research significance[8,9]. At present, there are the following three categories of methods for the early diagnosis of AD: diagnostic methods based on clinical symptoms and cognitive function examination scales, biomarker-based detection methods, and neuroimaging-based detection methods[10][11][12]. The diagnostic method, based on clinical symptoms and a cognitive function examination scale, can be used in the quantitative assessment of cognitive impairment, and has the advantages of easy operation, low cost, and standardized diagnosis. However, due to the lack of objective evidence, it is easy for the diagnosis to be detrimentally influenced by non-pathological subjective factors, which inevitably lead to clinical misdiagnosis.[13][14][15]. A biomarker-based detection method is used to diagnose the disease and judge the disease stage by measuring biomarker levels in patients. For example, β-amyloid 1-42 (Aβ 1-42 ), total tau protein (T-tau), and hyperphosphorylated tau (P-tau), the core biomarkers of AD that are mostly used in clinical practice, are derived from CSF and have shown high sensitivity and specificity in the identification of AD patients. Through providing effective diagnosis of AD in its early or asymptomatic stages, this approach may buy time for patients, increasing the effectiveness of treatment and reducing the disease incidence. However, this method cannot be used as a routine detection method due to the difficulty and traumatic nature of obtaining samples for determination of these biochemical indicators[16,17]. This problem can be circumvented when using neuroimage-based diagnostic methods. High-quality medical images, such as those acquired using positron emission computed tomography (PET) and magnetic resonance imaging (MRI), can provide doctors with more sufficient and subtle disease information, help doctors make diagnoses more quickly and accurately, and greatly reduce the misdiagnosis efficiency[18,19]. PET scans are performed after a patient is injected with a radioactive substance to see if there are lesions. However, PET has the disadvantages of poor specificity, low resolution, inaccurate anatomical positioning, and high cost[20]. MRI can clearly show the structure and anatomy of the human brain, which is conducive to the measurement and study of changes during brain atrophy in AD[21,22]. At present, the MRI diagnosis of AD is mainly based on subjective image reading by imaging doctors. This method is time consuming, laborious, and subjective, which will affect the accuracy in making judgments regarding the disease course. Hence, how to address these issues by using a computer to automatically and accurately classify MRI, and then identify MCI and AD has become a hot research topic in recent years[23,24].In the past ten years, deep learning and machine learning methods have achieved great success in the fields of speech recognition, computer vision, and image and video analysis[25]. More and more studies have applied convolutional neural network (CNN) combined with MRI imaging for the early diagnosis of AD[26]. The traditional CNN network is usually composed of an input layer, hidden layer, and output layer in series. The input layer is responsible for receiving input data[27]. The hidden layer is generally composed of multiple convolutional layers and pooling layers. Its function is to extract the layered features of the input images. This hierarchical structure can gradually extract the high-level features in the image. However, these methods have the following disadvantages: given the depth of the layers in the traditional CNN network structure, excessively deep networks can actually reduce the accuracy of classification to a certain extent[27,28]. Moreover, traditional CNN lacks invariance to the affine transformation of the image. This defect is caused by the CNN default sampling method (matrix sampling). The convolutional layer of traditional CNN cannot satisfactorily extract the long-distance correlation in the feature space. In order to solve the above problems, an improved deep residual network (ResNet) model, combining spatial transformer networks (STN) and a non-local attention mechanism, is proposed for the early diagnosis of AD[29][30][31].In this study, our key contributions are given below: Sensors 2021, 21, 4182 13 of 15classification accuracy of the algorithm proposed in this paper reached 97.1%, the macro precision reached 95.5%, the macro recall reached 95.3%, and the macro F1 value reached 95.4%, thus verifying the advantages of the proposed model. The proposed method has high significance in the practical application of AD. The combination of AD susceptibility gene detection and pattern recognition is our future research direction[71].</p>
<p>Introduction</p>
<p>Alzheimer's disease (AD) is a common, irreversible, progressive neurological disease characterized by cognitive impairment, whereby the patient's memory and thinking ability are slowly damaged over time [1,2]. AD is characterized by an insidious onset, slow progression, and irreversible course. Currently, there is no effective treatment that can reverse the damage caused by Alzheimer's disease [3,4]. At present, most patients with clinically diagnosed AD are in the middle or advanced stage, which means that the optimal time for treatment has already passed. Mild cognitive impairment (MCI) is an intermediate state between normal function and AD. It refers to a mild impairment of cognitive and memory functions rather than dementia [5,6]. According to statistics, the conversion rate of people with MCI to AD is significantly higher than that of healthy people [7]. Accurate diagnosis early in the course of the disease may allow patients to initiate preventive and intervention measures to slow or stop the progression of the disease before irreversible 1.</p>
<p>We propose a new ResNet model where a new Mish activation function is selected in the ResNet-50 backbone to replace the Relu function;</p>
<p>2.</p>
<p>The STN is introduced between the input layer and the improved ResNet-50 backbone. This enhances the spatial invariance of the model; 3.</p>
<p>A non-local attention mechanism is introduced between the fourth and fifth stages of the improved ResNet-50 backbone.</p>
<p>Related Work</p>
<p>In this section, we review studies related to the early diagnosis of AD. With the increasing attention given to MCI, more and more researchers have proposed new MCI prediction methods [32].</p>
<p>There are diagnostic methods based on the clinical symptom and cognitive function scale. Several AD screening scales commonly used in clinical practice include the clockdrawing test (CDT), mini-mental state examination (MMSE), Montreal cognitive assessment (MOCA), and Alzheimer's disease assessment scale (ADAS-COG), among others. [33][34][35]. Brodaty H. et al. [36] argued that a clock map is a very effective test screening measure for detecting mild or moderate AD in the clinical population, with very low false-negative and false-positive rates. Pozueta A. et al. [37] proposed that a combination of MMSE and CVLT-LDTR could distinguish PR-AD and S-MCI at the baseline. The analysis of these two neuropsychological predictors is relatively short and may be easily accomplished in a non-specialist clinical setting. Zainal N. et al. [38] proposed that ADAS-COG, which is widely used in clinical trials, may be suitable for an Asian cohort, and is useful for detecting MCI and mild AD. Roman F. et al. [39] proposed that Argentina-type MBT and MMSE were significantly correlated with memory cells and that they were effective tools for detecting MCI. The working characteristics of the MBT are very suitable, more so than those of other commonly used tests for detecting MCI. Carlew A. et al. [40] proposed that detection by MMSE is significantly affected by the disease course, while in the case of MOCA, severe MCI results in insignificant changes. Although statistically significant, the actual clinical significance of the changes in MOCA is unclear. The growing use of MOCA requires further research to understand what constitutes clinically significant changes and whether it is appropriate to track cognitive trajectories.</p>
<p>There are diagnostic methods based on biomarker detection; cerebrospinal fluid (CSF) biomarkers Aβ  , T-tau, and P-tau are well-validated, and are being increasingly used in clinical practice as tools for the affirmative diagnosis of AD [41]. The long-term stability of core CSF biomarkers in patients with AD provides further support for their use in clinical studies and treatment monitoring in clinical trials [42]. Michael E. et al. [43] proposed that CSF Aβ 1-42 showed the best diagnostic accuracy among the CSF biomarkers. At a sensitivity of 85%, the specificity in differentiating AD dementia from other diagnoses ranged from 42% to 77%. Geijselaers S. et al. [44] provided further evidence of the relationship between brain insulin signaling and AD pathology. This also highlights the need to consider sex and the APOE ε4 genotype during assessment. Gs A. et al. [45] proposed that blood, urine, saliva, and tears have yielded promising results, and several new molecules have been identified as potential brain biomarkers thanks to the development of new ultra-sensitive techniques. In this review, the authors discuss the advantages and limitations of classic CSF biomarkers for AD, as well as the latest prospects for new CSF candidate biomarkers and alternative substrates. Fossati S. et al. [46] found that plasma tau is higher in AD independently from CSF-tau. Importantly, adding plasma tau to CSF tau or P-tau improves the diagnostic accuracy, suggesting that plasma tau may represent a useful biomarker for AD, especially when added to CSF tau measures. Abe K. et al. [47] found that the present serum biomarker set provides a new, rapid, non-invasive, highly quantitative, and lowcost clinical application for dementia screening, and also suggests an alternative pathway or mechanism by which AD causes neuroinflammation and neurovascular unit damage. Nabers A. et al. [48] used immune infrared sensors to measure the secondary structure distribution of amyloid beta (Aβ) and tau in plasma and cerebrospinal fluid as structurebased biomarkers of AD. In the first diagnostic screening step, structure-based Aβ blood biomarkers support AD recognition with a sensitivity of 90%. In the second diagnostic There are also neuroimage-based detection methods. Basheera S. et al. [49] used a CNN model with inception blocks to extract depth features from gray matter slices for the early prediction of AD. Ji H. et al. [50] mainly studied the early diagnosis of AD using convolutional neural networks. The gray matter and white matter image slices of MRI were used as classification inputs. After a convolution operation combined with the output of deep learning classifier, an ensemble learning method was adopted to improve classification. Tofail B. et al. [51] proposed constructing multiple deep two-dimensional convolutional neural networks (2D-CNNs) to learn various features from local brain images and combine these features with the final classification for AD diagnosis. Subramoniam M. et al. [52] proposed a method for the prediction of AD from MRI based on deep neural networks. The state of image classification networks, such as VGG, residual network (ResNet), etc., with transfer learning, show promising results. The performance of pretrained versions of these networks can be improved by transfer learning. A ResNet-based architecture with a large number of layers was found to give the best result in terms of predicting different stages of the disease. Hussain et al. [53] proposed a model based on 12-layer CNN to use brain MRI data for the dichotomization and detection of AD.</p>
<p>Among the abovementioned methods available for the early diagnosis of AD, the diagnosis method based on MRI has the advantages of non-invasiveness and non-radioactivity, and has become an indispensable technical tool in the clinical and scientific research of AD. In this study, ResNet-50 is used as the backbone network because of its simpler structure, and since the increase in identity mapping does not reduce network performance. The proposed method can extract more information from layers by deepening the network structure through deep ResNet [54,55].</p>
<p>Materials and Methods</p>
<p>Data Selection</p>
<p>The data used in this study come from ADNI (Alzheimer disease neuroimaging initiative) (http://adni.loni.usc.edu (accessed on 16 February 2020)) [56]. Generally, the dataset is divided into the following 3 categories: normal control (NC), mild cognitive impairment (MCI), and Alzheimer's disease (AD). MCI is a major step in the transition from a normal to AD state. We screened a total of 515 samples, which were divided into 55 AD samples, 255 NC samples, and 205 MCI samples. The proportion of men and women in each category was roughly equal. MMSE mainly relies on experienced doctors to ask patients to obtain scale scores. The scale score is a continuous integer from 0 to 30. The higher the score, the healthier the patient, while the lower the score, the more severe the dementia. For NC, the MMSE score is 24-30 and the ADAS-Cog score is &lt;12. For MCI, the MMSE score is 23-30 and the ADAS-Cog score is 7-17. For AD, its MMSE score is 20-26 and the ADAS-Cog score is 12-29 [57]. Information on the collected data is shown in Table 1. </p>
<p>Deep Residual Neural Network</p>
<p>ResNet was proposed by 4 Chinese scientists, including Kaiming He, from the former Microsoft Research Institute, and the proposal of deep ResNet is a milestone event in the history of CNN images. The residual module in the deep ResNet is shown in Figure 1 [58]. </p>
<p>Deep Residual Neural Network</p>
<p>ResNet was proposed by 4 Chinese scientists, including Kaiming He, from the former Microsoft Research Institute, and the proposal of deep ResNet is a milestone event in the history of CNN images. The residual module in the deep ResNet is shown in Figure 1 [58]. In the figure, x is weighted by the first layer, then F(x) + x is obtained after the nonlinear variation in the Relu function and the weighting of the second layer. This is a linear stack, and the two layers constitute a residual learning module. The network composed of residual modules is called ResNet. The difference between the ResNet and the ordinary network is that the jump connection is introduced, which can help the information of the previous residual block flow into the next residual block without obstruction. The problem of vanishing gradient and degradation caused by too deep a network is avoided [58,59].</p>
<p>Since the Relu function often causes the permanent inactivation of neurons, these inactivated neurons will be occupied. Due to the computational resources involved, the ability to extract image features still needs to be improved. In order to make up for the deficiency of Relu, the new activation function Mish was selected to replace the function of Relu in the model. The Mish activation function is expressed as in Equation (1) [60], as follows:
= ℎ 1 +(1)
The positive value of the Mish activation function can reach any height, avoiding saturation due to capping. Due to the smoothness of the Mish activation curve, better information can be penetrated into the neural network, resulting in better accuracy and generalization. As the depth of the network increases, Mish can better maintain accuracy.</p>
<p>In the deep ResNet-50, the bottleneck residual module is stacked with a 1 × 1 convolution, 3 × 3 convolution, and 1 × 1 convolution. The two l × 1 convolutions play the role of decreasing and increasing dimensions, respectively. The bottleneck residual module can greatly improve the computational efficiency and significantly increase the depth of the residual block. The introduction of more Mish activation functions can improve the representation ability of ResNet. The bottleneck residuals module of different layers for the ResNet-50 architecture is expressed in Figure 2 [58][59][60]. In the figure, x is weighted by the first layer, then F(x) + x is obtained after the nonlinear variation in the Relu function and the weighting of the second layer. This is a linear stack, and the two layers constitute a residual learning module. The network composed of residual modules is called ResNet. The difference between the ResNet and the ordinary network is that the jump connection is introduced, which can help the information of the previous residual block flow into the next residual block without obstruction. The problem of vanishing gradient and degradation caused by too deep a network is avoided [58,59].</p>
<p>Since the Relu function often causes the permanent inactivation of neurons, these inactivated neurons will be occupied. Due to the computational resources involved, the ability to extract image features still needs to be improved. In order to make up for the deficiency of Relu, the new activation function Mish was selected to replace the function of Relu in the model. The Mish activation function is expressed as in Equation (1) [60], as follows:
f (x) = xtanh(ln(1 + e x ))(1)
The positive value of the Mish activation function can reach any height, avoiding saturation due to capping. Due to the smoothness of the Mish activation curve, better information can be penetrated into the neural network, resulting in better accuracy and generalization. As the depth of the network increases, Mish can better maintain accuracy.</p>
<p>In the deep ResNet-50, the bottleneck residual module is stacked with a 1 × 1 convolution, 3 × 3 convolution, and 1 × 1 convolution. The two l × 1 convolutions play the role of decreasing and increasing dimensions, respectively. The bottleneck residual module can greatly improve the computational efficiency and significantly increase the depth of the residual block. The introduction of more Mish activation functions can improve the representation ability of ResNet. The bottleneck residuals module of different layers for the ResNet-50 architecture is expressed in Figure 2 [58][59][60]. </p>
<p>Spatial Transformer Networks (STN)</p>
<p>STN can adaptively perform spatial transformation. In the case of large spatial differences in the input data, this network can be added to the existing convolutional network to improve the accuracy of classification. The STN network consists of a localization network, a grid generator, and a sampler, as shown in Figure 3 [61].  </p>
<p>Spatial Transformer Networks (STN)</p>
<p>STN can adaptively perform spatial transformation. In the case of large spatial differences in the input data, this network can be added to the existing convolutional network to improve the accuracy of classification. The STN network consists of a localization network, a grid generator, and a sampler, as shown in Figure 3 [61]. </p>
<p>Spatial Transformer Networks (STN)</p>
<p>STN can adaptively perform spatial transformation. In the case of large spatial differences in the input data, this network can be added to the existing convolutional network to improve the accuracy of classification. The STN network consists of a localization network, a grid generator, and a sampler, as shown in Figure 3 [61].  Localization net: localization net is traditional CNN and this is the network used for the regression transformation parameter θ.</p>
<p>Grid generator: the grid generator generates a coordinate network corresponding to each pixel of the output image in the input image. Sampler: a sampler uses the sampling network and the input element graph as an input, then inputs, then obtains the result after transforming the element graph.</p>
<p>After the input picture is passed through the STN module, the transformed picture is obtained, and the transformed picture is then input into the CNN network. Loss is calculated through the loss function, and the gradient is then calculated to update the θ parameter. Finally, the STN module will learn how to correct the picture [61,62].</p>
<p>Non-Local Attention Mechanism</p>
<p>The attention mechanism is a general mechanism for information acquisition, which is applied to scenarios where a large number of sources are used to obtain specific critical information and avoid processing all the data. The non-local attention mechanism directly captures remote dependencies by calculating the interaction between any two locations, rather than being limited to adjacent points. The non-local attention mechanism is shown in Figure 4 [63]. Grid generator: the grid generator generates a coordinate network corresponding to each pixel of the output image in the input image.</p>
<p>Sampler: a sampler uses the sampling network and the input element graph as an input, then inputs, then obtains the result after transforming the element graph.</p>
<p>After the input picture is passed through the STN module, the transformed picture is obtained, and the transformed picture is then input into the CNN network. Loss is calculated through the loss function, and the gradient is then calculated to update the θ parameter. Finally, the STN module will learn how to correct the picture [61,62].</p>
<p>Non-Local Attention Mechanism</p>
<p>The attention mechanism is a general mechanism for information acquisition, which is applied to scenarios where a large number of sources are used to obtain specific critical information and avoid processing all the data. The non-local attention mechanism directly captures remote dependencies by calculating the interaction between any two locations, rather than being limited to adjacent points. The non-local attention mechanism is shown in Figure 4 [63]. Three feature images, A, B, and C, can be obtained through three 1 × 1 convolutional layers. A and B are multiplied to obtain S using softmax. Then, the product of S and C can be multiplied by the scale coefficient to obtain D, D can be reshaped to the original shape, and then X is added to obtain the final output E. We can see that the value of each position of E is a weighted sum of the original feature and each position.</p>
<p>can be written as Equation (2) [63,64]. Three feature images, A, B, and C, can be obtained through three 1 × 1 convolutional layers. A and B are multiplied to obtain S using softmax. Then, the product of S and C can be multiplied by the scale coefficient to obtain D, D can be reshaped to the original shape, and then X is added to obtain the final output E. We can see that the value of each position of E is a weighted sum of the original feature and each position. E j can be written as Equation (2) [63,64].
= +(2)E j = α N ∑ i=1 (S ji C i ) + X i(2)</p>
<p>Proposed Method</p>
<p>In this paper, a new deep ResNet learning method that combines STN and the nonlocal attention mechanism is proposed. The model uses MRI slices of a large number of subjects to train the network, automatically learns image features, avoiding manual extraction, and then classifies the input images based on these features to obtain diagnosis results for the subject's state. In this study, a new activation function Mish was selected to replace Relu in the traditional ResNet-50 model. This method could solve the problem of local information loss in ordinary CNN and can satisfactorily extract the long-distance correlation in feature space. The framework of the proposed method is shown in Figure 5 [58][59][60][61][62][63][64][65].</p>
<p>Sensors 2021, 21, x FOR PEER REVIEW 8 of 15</p>
<p>Proposed Method</p>
<p>In this paper, a new deep ResNet learning method that combines STN and the nonlocal attention mechanism is proposed. The model uses MRI slices of a large number of subjects to train the network, automatically learns image features, avoiding manual extraction, and then classifies the input images based on these features to obtain diagnosis results for the subject's state. In this study, a new activation function Mish was selected to replace Relu in the traditional ResNet-50 model. This method could solve the problem of local information loss in ordinary CNN and can satisfactorily extract the long-distance correlation in feature space. The framework of the proposed method is shown in Figure 5 [58-65]. A local network is a network used in regression of transformation parameter θ. Its input is a feature image and its output is the spatial transformation of parameter θ through a series of hidden network layers. If a 2D affine transformation is required, θ is the output of a 6-dimensional (2 × 3) vector. The size of θ depends on the type of transformation applied.</p>
<p>A grid generator is used to build a sampling grid according to the predicted transformation parameters. It is the output of a group of points in the input image after sampling and transformation. What the grid generator actually obtains is a kind of mapping relation [62]. Assuming that the coordinate of each pixel of input image is ( , ), the coordinate of each pixel of output image is ( , ). The space transformation function is a twodimensional affine transformation function. The corresponding relationship between ( , ) and ( , ) can be written as Equation (3), as follows:
= = 1 = 1(3)
In Equation (3), S represents the coordinate point of the input feature image, T represents the coordinate point of the output feature image, and is the output of the local network.</p>
<p>The sampler in STN uses the sampling grid and the input feature map as the input to produce the output. Additionally, it obtains the result after the feature map is transformed. Further, n and m will traverse all coordinates of the original graph U, and refers to the pixel values of a point in the original graph U. Then, , denotes the coordinates of the corresponding point in the U graph to be found at the ith point in V. The denoted coordinates are those on the U graph. K denotes filling by different methods, usually using bilinear interpolation. The following Equation (4) is obtained [61,62]: A local network is a network used in regression of transformation parameter θ. Its input is a feature image and its output is the spatial transformation of parameter θ through a series of hidden network layers. If a 2D affine transformation is required, θ is the output of a 6-dimensional (2 × 3) vector. The size of θ depends on the type of transformation applied.</p>
<p>A grid generator is used to build a sampling grid according to the predicted transformation parameters. It is the output of a group of points in the input image after sampling and transformation. What the grid generator actually obtains is a kind of mapping relation T θ [62].</p>
<p>Assuming that the coordinate of each pixel of input image is (x s i , y s i ), the coordinate of each pixel of output image is (x t i , t t i ). The space transformation function T θ is a two-dimensional affine transformation function. The corresponding relationship between (x s i , y s i ) and (x t i , y t i ) can be written as Equation (3), as follows:
x s i y s i = T θ (G i ) = A θ   x t i y t i 1   = θ 11 θ 12 θ 13 θ 21 θ 22 θ 23   x t i y t i 1  (3)
In Equation (3), S represents the coordinate point of the input feature image, T represents the coordinate point of the output feature image, and A θ is the output of the local network.</p>
<p>The sampler in STN uses the sampling grid and the input feature map as the input to produce the output. Additionally, it obtains the result after the feature map is transformed. Further, n and m will traverse all coordinates of the original graph U, and U nm refers to the pixel values of a point in the original graph U. Then, x s i , y s i denotes the coordinates of the corresponding point in the U graph to be found at the ith point in V. The denoted coordinates are those on the U graph. K denotes filling by different methods, usually using bilinear interpolation. The following Equation (4) is obtained [61,62]:
V i = ∑ n ∑ m U nm max(0, 1 − |x s i − m|)max(0, 1 − |y s i − n|)(4)
Integrating the STN module between the input and ResNet allows the network to automatically learn how to transform the feature map, thus helping to reduce the overall Sensors 2021, 21, 4182 9 of 15 cost of network training. We locate the output value in the network, indicating how to transform each item of training data [61][62][63][64].</p>
<p>The non-local attention mechanism is embedded as a component in ResNet-50, and new weights are learned in transfer learning so that pretrained weights are not unavailable due to the introduction of new modules [63,65].</p>
<p>The architecture of the proposed method is shown in Table 2 [58]. The environment of this experiment is a Linux system, which is designed and realized by the Keras framework, and the model is trained using the Adam optimization algorithm. The experiment steps are as follows:</p>
<p>(1) The experiment uses two-dimensional slices as training data, so it is necessary to slice the three-dimensional MRI coronal plane. In order to ensure that the input image size of the classifier is consistent, this experiment unifies these slices into a size of 224 × 224. The experiment uses the CAT12 toolkit of the SPM12 software to preprocess the images. Image preprocessing includes format conversion, skull stripping, grayscale normalization, MRI slicing, and uniform sizing, etc. The detailed preprocessing process is shown in Figure 6; (2) The Keras experimental platform was built and the STN + ResNet + attention network model was designed; (3) The K-fold (K = 5) cross validation method was used to randomly divide the dataset, with 80% used as the training set and 20% used as the test set; (4) The training set was input into the network for training and the training results were obtained; (5) The optimal model parameters were saved and tested in the model using the test set data. The flow chart with detailed steps is shown in Figure 7. The flow chart with detailed steps is shown in Figure 7. The flow chart with detailed steps is shown in Figure 7. </p>
<p>Experimental Results and Discussion</p>
<p>We considered our result in the context of multi-class classification. The multi-classification data were transformed into two classification problems and a one-vs-rest strategy </p>
<p>Experimental Results and Discussion</p>
<p>We considered our result in the context of multi-class classification. The multiclassification data were transformed into two classification problems and a one-vs-rest strategy was adopted-that is, one category comprised positive samples and the other categories comprised negative samples [66][67][68][69][70].</p>
<p>TP i : the prediction is category i, the reality is category i. TN i : the prediction is other classes of category i, the reality is other classes of category i. FP i : the prediction is category i, the reality is other classes of category i. FN i : the prediction is other classes of category i, the reality is category i.</p>
<p>Each category was taken as a positive sample to calculate the total accuracy, precision, and recall values for each category. The accuracy can be expressed using Equation (5) The precision of a certain category can be understood as predicting the accuracy of the sample, expressed as Equation (6), as follows:
Precision i = TP i TP i + FP i(6)
The recall of a certain category can be understood as the extent to which the sample of category i, which was correctly predicted, covers the sample of category i in the sample set, expressed as Equation (7), as follows:
Recall i = TP i TP i + FN i(7)
To investigate the merits and demerits of classifiers under different categories, a macro average should be introduced. Macro-averaging refers to the mathematical average of the values of each statistical index of all types. Their calculation equations are expressed in Equations (8)-(10), as follows:
Precision macro = ∑ N i=1 Precision i N (8) Recall macro = ∑ N i=1 Recall i N (9) F1 macro = 2Precision macro Recall macro Precision macro + Recall macro(10)
The total confusion matrix is obtained by adding the values of each folded confusion matrix. For the convenience of calculating the Precision macro , Recall macro , and F1 macro , we use the average confusion matrix of multiple classifications. We divide the value of the total confusion matrix by five to get the average confusion matrix. The model proposed in this study was used for training and testing on the selected ADNI dataset, and the test results are shown in Table 3 [70]. For the purpose of illustrating the effectiveness of the method proposed in this paper, ResNet50 baseline, ResNet50 + Mish, and STN + ResNet50 + Mish were selected to conduct experiments using the same dataset. The Accuracy, Precision macro , Recall macro , and F1 macro of each model were, respectively, calculated as shown in Table 4. In this paper, the Accuracy, Precision macro , Recall macro , and F1 macro value of the above models were successively compared and analyzed, as shown in Figure 8. experiments using the same dataset. The Accuracy, Precisionmacro, Recallmacro, and F1macro of each model were, respectively, calculated as shown in Table 4. In this paper, the Accuracy, Precisionmacro, Recallmacro, and F1macro value of the above models were successively compared and analyzed, as shown in Figure 8. The experimental results show that the method proposed in this article is compared with the other three methods in classification accuracy. There is a big improvement, and the standard deviation of the experimental results is smaller. The experiments show that the Mish activation function is used to replace the Relu function in the model, and the accuracy is increased by 1.9% compared with the baseline. After the introduction of the STN and attention mechanism, the accuracy of the model increased by 5.8%.</p>
<p>Conclusions</p>
<p>In this research article, we propose a deep learning model based on ResNet-50 for the early diagnosis of Alzheimer's disease. In the model, a new Mish activation function is selected in the ResNet-50 backbone to replace the Relu function, the STN is introduced between the input layer and the improved ResNet-50 backbone, and a non-local attention mechanism is introduced between the fourth and fifth stages of the improved ResNet-50 backbone. The Mish activation function is boundless (that is, the positive value can reach any height) to avoid saturation due to capping. Theoretically, the slight bias toward the negative values allows for better gradient flows in comparison with the hard zero boundary, as in Relu. Integrating the STN module into the ResNet-50 network allows the network to automatically learn how to transform the feature map, thus helping to reduce the overall cost of network training. The addition of a non-local block attention mechanism module provides a solid improvement. The proposed method was validated using the ADNI experimental dataset and compared with the ResNet-50 baseline, ResNet-50 + Mish, and STN + ResNet-50 + Mish models. The experimental results show that the proposed model is more effective and provides a better robustness for clinical application. The The experimental results show that the method proposed in this article is compared with the other three methods in classification accuracy. There is a big improvement, and the standard deviation of the experimental results is smaller. The experiments show that the Mish activation function is used to replace the Relu function in the model, and the accuracy is increased by 1.9% compared with the baseline. After the introduction of the STN and attention mechanism, the accuracy of the model increased by 5.8%.</p>
<p>Conclusions</p>
<p>In this research article, we propose a deep learning model based on ResNet-50 for the early diagnosis of Alzheimer's disease. In the model, a new Mish activation function is selected in the ResNet-50 backbone to replace the Relu function, the STN is introduced between the input layer and the improved ResNet-50 backbone, and a non-local attention mechanism is introduced between the fourth and fifth stages of the improved ResNet-50 backbone. The Mish activation function is boundless (that is, the positive value can reach any height) to avoid saturation due to capping. Theoretically, the slight bias toward the negative values allows for better gradient flows in comparison with the hard zero boundary, as in Relu. Integrating the STN module into the ResNet-50 network allows the network to automatically learn how to transform the feature map, thus helping to reduce the overall cost of network training. The addition of a non-local block attention mechanism module provides a solid improvement. The proposed method was validated using the ADNI experimental dataset and compared with the ResNet-50 baseline, ResNet-50 + Mish, and STN + ResNet-50 + Mish models. The experimental results show that the proposed model is more effective and provides a better robustness for clinical application. The integration with STN enhances the ability of this model to extract network features by improving the spatial invariance of the network. This demonstrates its good recognition effect. The introduction of a non-local block attention mechanism can enhance model robustness. In the end, the experiment results found using the ADNI dataset show that the</p>
<p>, the combination of structure-based cerebrospinal fluid biomarkers Aβ and tau allowed the exclusion of false positives, with an overall specificity of 97%.</p>
<p>Figure 1 .
1The residual block of the residual network.</p>
<p>Figure 1 .
1The residual block of the residual network.</p>
<p>Figure 2 .
2Bottleneck residuals module of different layers for the ResNet-50 architecture. (a) Stage 2, (b) stage 3, (c) stage 4, (d) stage 5.</p>
<p>Figure 3 .
3The STN module.Localization net: localization net is traditional CNN and this is the network used for the regression transformation parameter θ.</p>
<p>Figure 2 .
2Bottleneck residuals module of different layers for the ResNet-50 architecture. (a) Stage 2, (b) stage 3, (c) stage 4, (d) stage 5.</p>
<p>Figure 2 .
2Bottleneck residuals module of different layers for the ResNet-50 architecture. (a) Stage 2, (b) stage 3, (c) stage 4, (d) stage 5.</p>
<p>Figure 3 .
3The STN module.Localization net: localization net is traditional CNN and this is the network used for the regression transformation parameter θ.</p>
<p>Figure 3 .
3The STN module.</p>
<p>Figure 4 .
4Non-local attention mechanism.</p>
<p>Figure 4 .
4Non-local attention mechanism.</p>
<p>Figure 5 .
5The framework of the proposed method.</p>
<p>Figure 5 .
5The framework of the proposed method.</p>
<p>Sensors 2021 , 15 Figure 6 .
202115621, x FOR PEER REVIEW 10 of Preprocessing flow chart.</p>
<p>Figure 6 .
6Preprocessing flow chart.</p>
<p>Figure 6 .
6Preprocessing flow chart.</p>
<p>Figure 7 .
7The detailed step flow chart.</p>
<p>Figure 7 .
7The detailed step flow chart.</p>
<p>Figure 8 .
8Comparison of the Accuracy, Precisionmacro, Recallmacro, and F1macro value.</p>
<p>Figure 8 .
8Comparison of the Accuracy, Precision macro , Recall macro , and F1 macro value.</p>
<p>Table 1 .
1Information of subjects from ADNI dataset used in this study.Dataset 
ADNI </p>
<p>Diagnosis 
NC 
MCI 
AD </p>
<p>Number of samples 
255 
205 
55 
Number of female samples 
127 
103 
27 
Number of male samples 
128 
102 
28 
Age 
70.6 ± 5.1 
73.8 ± 7.5 
78.9 ± 8.6 
ADAS-Cog 
&lt;12 
7-17 
12-29 
MMSE 
24-30 
23-30 
20-26 </p>
<p>Table 2 .
2The architecture of the proposed method.Layer Name 
Output Size 
Layer </p>
<p>STN 
224 × 224 
Localization network, grid generator, sampler </p>
<p>Conv1 
112 × 112 
7 × 7, 64, stride 2 </p>
<p>Max pooling 
56 × 56 
3 × 3, stride 2 </p>
<p>Stage 2 
56 × 56 </p>
<p> </p>
<p> </p>
<p>1 × 1, 64 
3 × 3, 64 
1 × 1, 256 </p>
<p> </p>
<p> × 3, Mish </p>
<p>Stage 3 
28 × 28 </p>
<p> </p>
<p> </p>
<p>1 × 1, 128 
3 × 3, 128 
1 × 1, 512 </p>
<p> </p>
<p> × 4, Mish </p>
<p>Stage 4 
14 × 14 </p>
<p> </p>
<p> </p>
<p>1 × 1, 256 
3 × 3, 256 
1 × 1, 1024 </p>
<p> </p>
<p> × 6, Mish </p>
<p>Non-local attention module 
14 × 14 
Attention × 1 </p>
<p>Stage 5 
7 × 7 </p>
<p> </p>
<p> </p>
<p>1 × 1, 512 
3 × 3, 512 
1 × 1, 2048 </p>
<p> </p>
<p> × 3, Mish </p>
<p>Average pooling 
1 × 1 
7 × 7, stride 1 </p>
<p>FC, softmax 
1000-d </p>
<p>Table 3 .
3Average confusion matrix and experimental results.Confusion Matrix </p>
<p>Predicted Class 
Recall 
NC 
MCI 
AD </p>
<p>Actual Class </p>
<p>NC 
51 
0 
0 
1.000 </p>
<p>Recall macro = 0.953 
MCI 
1 
39 
1 
0.951 </p>
<p>AD 
0 
1 
10 
0.909 </p>
<p>Precision </p>
<p>0.981 
0.975 
0.909 
Acc = 0.971 
F1 macro = 0.954 
Precision macro = 0.955 </p>
<p>Table 4 .
4Performance comparison of the proposed classification method.Model 
Accuracy 
Precision macro 
Recall macro 
F1 macro </p>
<p>ResNet50 baseline 
0.913 ± 0.035 
0.871 ± 0.033 
0.887 ± 0.032 
0.879 
ResNet50 + Mish 
0.932 ± 0.032 
0.893 ± 0.030 
0.924 ± 0.028 
0.908 
STN + ResNet50 + Mish 
0.951 ± 0.021 
0.940 ± 0.023 
0.939 ± 0.021 
0.939 
Proposed method 
0.971 ± 0.016 
0.955 ± 0.015 
0.953 ± 0.018 
0.954 </p>
<p>Table 4 .
4Performance comparison of the proposed classification method.Model 
Accuracy 
Precisionmacro 
Recallmacro 
F1macro 
ResNet50 baseline 
0.913 ± 0.035 0.871 ± 0.033 
0.887 ± 0.032 
0.879 
ResNet50 + Mish 
0.932 ± 0.032 0.893 ± 0.030 
0.924 ± 0.028 
0.908 
STN + ResNet50 + Mish 0.951 ± 0.021 0.940 ± 0.023 
0.939 ± 0.021 
0.939 
Proposed method 
0.971 ± 0.016 0.955 ± 0.015 
0.953 ± 0.018 
0.954 </p>
<p>Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. W J Lukiw, A Vergallo, S Lista, H Hampel, Y Zhao, 10.3390/jpm10030138J. Pers. Med. 10PubMedLukiw, W.J.; Vergallo, A.; Lista, S.; Hampel, H.; Zhao, Y. Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. J. Pers. Med. 2020, 10, 138. [CrossRef] [PubMed]</p>
<p>Peripheral Biomarkers for Alzheimer's Disease: Update and Progress. M N Sabbagh, K Blennow, 10.1007/s40120-019-00171-6Neurol. Ther. 8Sabbagh, M.N.; Blennow, K. Peripheral Biomarkers for Alzheimer's Disease: Update and Progress. Neurol. Ther. 2019, 8, 33-36. [CrossRef]</p>
<p>Blood tests to screen for Alzheimer's disease. M Husain, 10.1093/brain/awaa462Brain. 144PubMedHusain, M. Blood tests to screen for Alzheimer's disease. Brain 2021, 144, 355-356. [CrossRef] [PubMed]</p>
<p>Alzheimer's disease. C A Lane, J Hardy, J M Schott, 10.1111/ene.13439Eur. J. Neurol. 25PubMedLane, C.A.; Hardy, J.; Schott, J.M. Alzheimer's disease. Eur. J. Neurol. 2018, 25, 59-70. [CrossRef] [PubMed]</p>
<p>Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview. B Rma, C At, D Rrc, Clin. Biochem. 73Rma, B.; At, C.; Rrc, D. Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropatho- logical overview. Clin. Biochem. 2019, 73, 26-31.</p>
<p>Cognitive Training and Stress Detection in MCI Frail Older People Through Wearable Sensors and Machine Learning. F Delmastro, F Di Martino, C Dolciotti, 10.1109/ACCESS.2020.2985301IEEE Access. 8Delmastro, F.; Di Martino, F.; Dolciotti, C. Cognitive Training and Stress Detection in MCI Frail Older People Through Wearable Sensors and Machine Learning. IEEE Access 2020, 8, 65573-65590. [CrossRef]</p>
<p>Early diagnosis of Alzheimer's disease with deep learning. S Q Liu, S D Liu, W D Cai, Proceedings of the 2014 IEEE 11th International Symposium on Biomedical Imaging (ISBI). the 2014 IEEE 11th International Symposium on Biomedical Imaging (ISBI)Beijing, ChinaLiu, S.Q.; Liu, S.D.; Cai, W.D. Early diagnosis of Alzheimer's disease with deep learning. In Proceedings of the 2014 IEEE 11th International Symposium on Biomedical Imaging (ISBI), Beijing, China, 29 April-2 May 2014; pp. 1015-1018.</p>
<p>Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). A Brugnolo, N Girtler, M Pardini, E Doglione, B Orso, F Massa, M I Donegani, M Bauckneht, S Morbelli, D Arnaldi, 10.3390/diagnostics1101010811PubMedBrugnolo, A.; Girtler, N.; Pardini, M.; Doglione, E.; Orso, B.; Massa, F.; Donegani, M.I.; Bauckneht, M.; Morbelli, S.; Arnaldi, D.; et al. Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). Diagnostics 2021, 11, 108. [CrossRef] [PubMed]</p>
<p>A novel conversion prediction method of MCI to AD based on longitudinal dynamic morphological features using ADNI structural MRIs. M Guo, Y Li, W Zheng, K Huang, L Zhou, X Hu, Z Yao, B Hu, 10.1007/s00415-020-09890-5J. Neurol. 2020PubMedGuo, M.; Li, Y.; Zheng, W.; Huang, K.; Zhou, L.; Hu, X.; Yao, Z.; Hu, B. A novel conversion prediction method of MCI to AD based on longitudinal dynamic morphological features using ADNI structural MRIs. J. Neurol. 2020, 1-15. [CrossRef] [PubMed]</p>
<p>Biomarkers for the Early Detection and Progression of Alzheimer's Disease. S E Counts, M D Ikonomovic, N Mercado, I E Vega, E J Mufson, 10.1007/s13311-016-0481-zNeurotherapeutics. 14PubMedCounts, S.E.; Ikonomovic, M.D.; Mercado, N.; Vega, I.E.; Mufson, E.J. Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics 2017, 14, 35-53. [CrossRef] [PubMed]</p>
<p>Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. H Hampel, 10.1038/nrd3115Nat. Rev. Drug Discov. 9Hampel, H. Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9, 560-574. [CrossRef]</p>
<p>Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia. A Zhao, Y Li, Y Yan, Y Qiu, B Li, W Xu, Y Wang, J Liu, Y Deng, 10.1186/s40035-020-00210-5Transl. Neurodegener. 2020PubMedZhao, A.; Li, Y.; Yan, Y.; Qiu, Y.; Li, B.; Xu, W.; Wang, Y.; Liu, J.; Deng, Y. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia. Transl. Neurodegener. 2020, 9, 1-10. [CrossRef] [PubMed]</p>
<p>Screening for mild cognitive impairment: A systematic review. J A Lonie, K M Tierney, K P Ebmeier, 10.1002/gps.2208Int. J. Geriatr. Psychiatry. 24Lonie, J.A.; Tierney, K.M.; Ebmeier, K.P. Screening for mild cognitive impairment: A systematic review. Int. J. Geriatr. Psychiatry 2009, 24, 902-915. [CrossRef]</p>
<p>MMSE Subscale Scores as Useful Predictors of AD Conversion in Mild Cognitive Impairment. Y M Choe, B C Lee, I.-G Choi, G.-H Suh, D Y Lee, J W Kim, 10.2147/NDT.S263702Neuropsychiatr. Dis. Treat. 16Choe, Y.M.; Lee, B.C.; Choi, I.-G.; Suh, G.-H.; Lee, D.Y.; Kim, J.W. MMSE Subscale Scores as Useful Predictors of AD Conversion in Mild Cognitive Impairment. Neuropsychiatr. Dis. Treat. 2020, 16, 1767-1775. [CrossRef]</p>
<p>The Mini-Cog versus the Mini-Mental State Examination and the Clock Drawing Test in daily clinical practice: Screening value in a German Memory Clinic. M Milian, A.-M Leiherr, G Straten, S Müller, T Leyhe, G W Eschweiler, 10.1017/S1041610211002286Int. Psychogeriatr. 24Milian, M.; Leiherr, A.-M.; Straten, G.; Müller, S.; Leyhe, T.; Eschweiler, G.W. The Mini-Cog versus the Mini-Mental State Examination and the Clock Drawing Test in daily clinical practice: Screening value in a German Memory Clinic. Int. Psychogeriatr. 2011, 24, 766-774. [CrossRef]</p>
<p>Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease. Front. L F Inmaculada, C I Inmaculada, S E Aitana, Neurol. 6125Inmaculada, L.F.; Inmaculada, C.I.; Aitana, S.E. Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease. Front. Neurol. 2015, 6, 125.</p>
<p>Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. C Delaby, L Muñoz, S Torres, 10.1016/j.cca.2018.12.021Clin. Chim. Acta. 490PubMedDelaby, C.; Muñoz, L.; Torres, S. Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clin. Chim. Acta 2019, 490, 98-101. [CrossRef] [PubMed]</p>
<p>Towards harmonizing subtyping methods for PET and MRI studies of Alzheimer's disease. Alzheimer's Dement. 2020, 16, e042807. R Mohanty, G Mårtensson, K Poulakis, E Rodriguez-Vieitez, M Grothe, A K Nordberg, D Ferreira, E Westman, 10.1002/alz.042807Mohanty, R.; Mårtensson, G.; Poulakis, K.; Rodriguez-Vieitez, E.; Grothe, M.; Nordberg, A.K.; Ferreira, D.; Westman, E. Towards harmonizing subtyping methods for PET and MRI studies of Alzheimer's disease. Alzheimer's Dement. 2020, 16, e042807. [CrossRef]</p>
<p>Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloidand 18F-FDG-PET imaging. J Ottoy, E Niemantsverdriet, J Verhaeghe, E De Roeck, H Struyfs, C Somers, L Wyffels, S Ceyssens, S Van Mossevelde, T V D Bossche, 10.1016/j.nicl.2019.101771NeuroImage Clin. 22PubMedOttoy, J.; Niemantsverdriet, E.; Verhaeghe, J.; De Roeck, E.; Struyfs, H.; Somers, C.; Wyffels, L.; Ceyssens, S.; Van Mossevelde, S.; Bossche, T.V.D.; et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. NeuroImage Clin. 2019, 22, 101771. [CrossRef] [PubMed]</p>
<p>Early identification of MCI converting to AD: A FDG PET study. M Pagani, F Nobili, S Morbelli, D Arnaldi, A Giuliani, J Öberg, N Girtler, A Brugnolo, A Picco, M Bauckneht, 10.1007/s00259-017-3761-xEur. J. Nucl. Med. Mol. Imaging. 44Pagani, M.; Nobili, F.; Morbelli, S.; Arnaldi, D.; Giuliani, A.; Öberg, J.; Girtler, N.; Brugnolo, A.; Picco, A.; Bauckneht, M.; et al. Early identification of MCI converting to AD: A FDG PET study. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 2042-2052. [CrossRef]</p>
<p>Convolutional Neural Network-based MR Image Analysis for Alzheimer's Disease Classification. B.-K Choi, N Madusanka, H.-K Choi, J.-H So, C.-H Kim, H.-G Park, S Bhattacharjee, D Prakash, 10.2174/1573405615666191021123854Curr. Med. Imaging Rev. 16PubMedChoi, B.-K.; Madusanka, N.; Choi, H.-K.; So, J.-H.; Kim, C.-H.; Park, H.-G.; Bhattacharjee, S.; Prakash, D. Convolutional Neural Network-based MR Image Analysis for Alzheimer's Disease Classification. Curr. Med. Imaging Rev. 2020, 16, 27-35. [CrossRef] [PubMed]</p>
<p>Effects of mind body exercise on brain structure and function a systematic review on MRI studies. L Lin, Brain Sci. 2021205Lin, L. Effects of mind body exercise on brain structure and function a systematic review on MRI studies. Brain Sci. 2021, 11, 205.</p>
<p>Exploiting Discriminative Regions of Brain Slices Based on 2D CNNs for Alzheimer's Disease Classification. F Ren, C Yang, Q Qiu, N Zeng, C Cai, C Hou, Q Zou, 10.1109/ACCESS.2019.2920241IEEE Access. 7Ren, F.; Yang, C.; Qiu, Q.; Zeng, N.; Cai, C.; Hou, C.; Zou, Q. Exploiting Discriminative Regions of Brain Slices Based on 2D CNNs for Alzheimer's Disease Classification. IEEE Access 2019, 7, 181423-181433. [CrossRef]</p>
<p>Survey on identification of Alzheimer disease using magnetic resonance imaging (MRI) images. S Sumanth, A Suresh, Int. J. Innov. Technol. Explor. Eng. 8Sumanth, S.; Suresh, A. Survey on identification of Alzheimer disease using magnetic resonance imaging (MRI) images. Int. J. Innov. Technol. Explor. Eng. 2019, 8, 3564-3570.</p>
<p>GGA: A modified Genetic Algorithm with Gradient-based Local Search for Solving Constrained Optimization Problems. G D&apos;angelo, F Palmieri, 10.1016/j.ins.2020.08.040Inf. Sci. 547D'Angelo, G.; Palmieri, F. GGA: A modified Genetic Algorithm with Gradient-based Local Search for Solving Constrained Optimization Problems. Inf. Sci. 2020, 547, 136-162. [CrossRef]</p>
<p>A Deep Siamese Convolution Neural Network for Multi-Class Classification of Alzheimer Disease. A Mehmood, M Maqsood, M Bashir, Y Shuyuan, 10.3390/brainsci10020084Brain Sci. 2020PubMedMehmood, A.; Maqsood, M.; Bashir, M.; Shuyuan, Y. A Deep Siamese Convolution Neural Network for Multi-Class Classification of Alzheimer Disease. Brain Sci. 2020, 10, 84. [CrossRef] [PubMed]</p>
<p>Alzheimer's Diseases Detection by Using Deep Learning Algorithms: A Mini-Review. S Al-Shoukry, T H Rassem, N M Makbol, 10.1109/ACCESS.2020.2989396IEEE Access. 8Al-Shoukry, S.; Rassem, T.H.; Makbol, N.M. Alzheimer's Diseases Detection by Using Deep Learning Algorithms: A Mini-Review. IEEE Access 2020, 8, 77131-77141. [CrossRef]</p>
<p>Diagnosis of Alzheimer's Disease Severity with fMRI Images Using Robust Multitask Feature Extraction Method and Convolutional Neural Network (CNN). M Amini, M Pedram, A Moradi, M Ouchani, 10.1155/2021/5514839Comput. Math. Methods Med. PubMedAmini, M.; Pedram, M.; Moradi, A.; Ouchani, M. Diagnosis of Alzheimer's Disease Severity with fMRI Images Using Robust Mul- titask Feature Extraction Method and Convolutional Neural Network (CNN). Comput. Math. Methods Med. 2021, 2021, 5514839. [CrossRef] [PubMed]</p>
<p>Representation and Classification of Auroral Images Based on Convolutional Neural Networks. Q Yang, P Zhou, 10.1109/JSTARS.2020.2969245IEEE J. Sel. Top. Appl. Earth Obs. Remote Sens. 13Yang, Q.; Zhou, P. Representation and Classification of Auroral Images Based on Convolutional Neural Networks. IEEE J. Sel. Top. Appl. Earth Obs. Remote Sens. 2020, 13, 523-534. [CrossRef]</p>
<p>Malware Detection Algorithm Based on the Attention Mechanism and ResNet. L Wang, B Wang, P Zhao, R Liu, J Liu, Q Miao, 10.1049/cje.2020.09.006Chin. J. Electron. 29Wang, L.; Wang, B.; Zhao, P.; Liu, R.; Liu, J.; Miao, Q. Malware Detection Algorithm Based on the Attention Mechanism and ResNet. Chin. J. Electron. 2020, 29, 1054-1060. [CrossRef]</p>
<p>Spatial non-local attention for thoracic disease diagnosis and visualisation in weakly supervised learning. IET Image Process. M Yang, D Li, W Zhang, 10.1049/iet-ipr.2019.003213Yang, M.; Li, D.; Zhang, W. Spatial non-local attention for thoracic disease diagnosis and visualisation in weakly supervised learning. IET Image Process. 2019, 13, 1922-1930. [CrossRef]</p>
<p>Early diagnosis model of Alzheimer's disease based on sparse logistic regression with the generalized elastic net. R Xiao, X Cui, H Qiao, X Zheng, Y Zhang, C Zhang, X Liu, 10.1016/j.bspc.2020.102362Biomed. Signal Process. Control. 66Xiao, R.; Cui, X.; Qiao, H.; Zheng, X.; Zhang, Y.; Zhang, C.; Liu, X. Early diagnosis model of Alzheimer's disease based on sparse logistic regression with the generalized elastic net. Biomed. Signal Process. Control 2021, 66, 102362. [CrossRef]</p>
<p>Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. J Fortea, E Vilaplana, M Carmona-Iragui, 10.1016/S0140-6736(20)30689-9Lancet. 395Fortea, J.; Vilaplana, E.; Carmona-Iragui, M. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. Lancet 2020, 395, 1988-1997. [CrossRef]</p>
<p>A Novel Computerized Cognitive Stress Test to Detect Mild Cognitive Impairment. R C Cid, E Crocco, M Kitaigorodsky, L Beaufils, P Peña, G Grau, U Visser, D Loewenstein, 10.14283/jpad.2021.1J. Prev. 8Alzheimer's DisCid, R.C.; Crocco, E.; Kitaigorodsky, M.; Beaufils, L.; Peña, P.; Grau, G.; Visser, U.; Loewenstein, D. A Novel Computerized Cognitive Stress Test to Detect Mild Cognitive Impairment. J. Prev. Alzheimer's Dis. 2021, 8, 135-141. [CrossRef]</p>
<p>Early Cognitive Assessment Following Acute Stroke: Feasibility and Comparison between Mini-Mental State Examination and Montreal Cognitive Assessment. S Suda, K Muraga, A Ishiwata, T Nishimura, J Aoki, T Kanamaru, K Suzuki, Y Sakamoto, T Katano, K Nagai, 10.1016/j.jstrokecerebrovasdis.2020.104688J. Stroke Cerebrovasc. Dis. 29PubMedSuda, S.; Muraga, K.; Ishiwata, A.; Nishimura, T.; Aoki, J.; Kanamaru, T.; Suzuki, K.; Sakamoto, Y.; Katano, T.; Nagai, K.; et al. Early Cognitive Assessment Following Acute Stroke: Feasibility and Comparison between Mini-Mental State Examination and Montreal Cognitive Assessment. J. Stroke Cerebrovasc. Dis. 2020, 29, 104688. [CrossRef] [PubMed]</p>
<p>The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic. H Brodaty, C M Moore, 10.1002/(SICI)1099-1166(199706)12:6&lt;619::AID-GPS554&gt;3.0.CO;2-HInt. J. Geriatr. Psychiatry. 12Brodaty, H.; Moore, C.M. The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic. Int. J. Geriatr. Psychiatry 1997, 12, 619-627. [CrossRef]</p>
<p>Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test. A Pozueta, E Rodríguez-Rodríguez, J L Vazquez-Higuera, 10.1186/1471-2377-11-78BMC Neurol. 11PubMedPozueta, A.; Rodríguez-Rodríguez, E.; Vazquez-Higuera, J.L. Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test. BMC Neurol. 2011, 11, 78. [CrossRef] [PubMed]</p>
<p>Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context. Ann. N H Zainal, E Silva, L L Lim, Acad. Med. Singap. 45PubMedZainal, N.H.; Silva, E.; Lim, L.L. Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context. Ann. Acad. Med. Singap. 2016, 45, 273. [PubMed]</p>
<p>Validation of the Argentine version of the Memory Binding Test (MBT) for Early Detection of Mild Cognitive Impairment. F Roman, M Iturry, G Rojas, E Barceló, H Buschke, R F Allegri, 10.1590/S1980-5764-2016DN1003008Dement. Neuropsychol. 10Roman, F.; Iturry, M.; Rojas, G.; Barceló, E.; Buschke, H.; Allegri, R.F. Validation of the Argentine version of the Memory Binding Test (MBT) for Early Detection of Mild Cognitive Impairment. Dement. Neuropsychol. 2016, 10, 217-226. [CrossRef]</p>
<p>A-02 Comparing Rate of Change in MoCA and MMSE Scores over Time in an MCI and AD sample. A Carlew, W Goette, K Womack, Arch. Clin. Neuropsychol. 356Carlew, A.; Goette, W.; Womack, K. A-02 Comparing Rate of Change in MoCA and MMSE Scores over Time in an MCI and AD sample. Arch. Clin. Neuropsychol. 2020, 35, 6.</p>
<p>State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm. E Solje, A Benussi, E Buratti, A Remes, A Haapasalo, B Borroni, 10.3390/diagnostics11050788Diagnostics 2021, 11, 788. [CrossRefSolje, E.; Benussi, A.; Buratti, E.; Remes, A.; Haapasalo, A.; Borroni, B. State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm. Diagnostics 2021, 11, 788. [CrossRef]</p>
<p>C Liguori, F P Paoletti, F Placidi, R Ruffini, G M Sancesario, P Eusebi, N B Mercuri, L Parnetti, 10.1007/s11910-019-0918-yCSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD. 19PubMedLiguori, C.; Paoletti, F.P.; Placidi, F.; Ruffini, R.; Sancesario, G.M.; Eusebi, P.; Mercuri, N.B.; Parnetti, L. CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD. Curr. Neurol. Neurosci. Rep. 2019, 19, 3. [CrossRef] [PubMed]</p>
<p>CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. E Michael, 11Alzheimer's DementMichael, E. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. Alzheimer's Dement. 2015, 11, 1306-1315.</p>
<p>Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. J. Alzheimer's Dis. S L Geijselaers, P Aalten, I H Ramakers, P P De Deyn, A C Heijboer, H L Koek, M G Olderikkert, J M Papma, F E Reesink, L L Smits, 10.3233/JAD-17052261Geijselaers, S.L.; Aalten, P.; Ramakers, I.H.; De Deyn, P.P.; Heijboer, A.C.; Koek, H.L.; OldeRikkert, M.G.; Papma, J.M.; Reesink, F.E.; Smits, L.L.; et al. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. J. Alzheimer's Dis. 2017, 61, 309-320. [CrossRef]</p>
<p>AD biomarker discovery in CSF and in alternative matrices. A Gs, B Sb, Clin. Biochem. 72Gs, A.; Sb, B. AD biomarker discovery in CSF and in alternative matrices. Clin. Biochem. 2019, 72, 52-57.</p>
<p>Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. S Fossati, J R Cejudo, L Debure, 10.1016/j.dadm.2019.05.001Diagn. Assess. Dis. Monit. 11Alzheimer's Dement. PubMedFossati, S.; Cejudo, J.R.; Debure, L. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. Alzheimer's Dement. Diagn. Assess. Dis. Monit. 2019, 11, 483-492. [CrossRef] [PubMed]</p>
<p>A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology. K Abe, J Shang, X Shi, T Yamashita, N Hishikawa, M Takemoto, R Morihara, Y Nakano, Y Ohta, K Deguchi, 10.3233/JAD-191016J. 73Alzheimer's DisAbe, K.; Shang, J.; Shi, X.; Yamashita, T.; Hishikawa, N.; Takemoto, M.; Morihara, R.; Nakano, Y.; Ohta, Y.; Deguchi, K.; et al. A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology. J. Alzheimer's Dis. 2020, 73, 217-227. [CrossRef]</p>
<p>Aβ and tau structure-based biomarkers for a blood-and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease. Alzheimer's Dement. A Nabers, H Hafermann, J Wiltfang, 10.1016/j.dadm.2019.01.008Diagn. Assess. Dis. Monit. 11Nabers, A.; Hafermann, H.; Wiltfang, J. Aβ and tau structure-based biomarkers for a blood-and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease. Alzheimer's Dement. Diagn. Assess. Dis. Monit. 2019, 11, 257-263. [CrossRef]</p>
<p>A novel CNN based Alzheimer's disease classification using hybrid enhanced ICA segmented gray matter of MRI. S Basheera, M S S Ram, 10.1016/j.compmedimag.2020.101713Comput. Med. Imaging Graph. 81Basheera, S.; Ram, M.S.S. A novel CNN based Alzheimer's disease classification using hybrid enhanced ICA segmented gray matter of MRI. Comput. Med. Imaging Graph. 2020, 81, 101713. [CrossRef]</p>
<p>Early diagnosis of Alzheimer's disease using deep learning. H Ji, Z Liu, W Q Yan, R Klette, ACM International Conference Proceeding Series. New York, NY, USAAssociation for Computing MachineryJi, H.; Liu, Z.; Yan, W.Q.; Klette, R. Early diagnosis of Alzheimer's disease using deep learning. In ACM International Conference Proceeding Series; Association for Computing Machinery: New York, NY, USA, 2019; pp. 87-91.</p>
<p>Binary Classification of Alzheimer's Disease Using sMRI Imaging Modality and Deep Learning. A Bin Tufail, Y.-K Ma, Q.-N Zhang, 10.1007/s10278-019-00265-5J. Digit. Imaging. 33Bin Tufail, A.; Ma, Y.-K.; Zhang, Q.-N. Binary Classification of Alzheimer's Disease Using sMRI Imaging Modality and Deep Learning. J. Digit. Imaging 2020, 33, 1073-1090. [CrossRef]</p>
<p>Deep learning based prediction of Alzheimer's disease from magnetic resonance images. M Subramoniam, T R Aparna, P R Anurenjan, K G Sreeni, arXiv:2101.04961v12020Subramoniam, M.; Aparna, T.R.; Anurenjan, P.R.; Sreeni, K.G. Deep learning based prediction of Alzheimer's disease from magnetic resonance images. arXiv 2020, arXiv:2101.04961v1.</p>
<p>Deep Learning Based Binary Classification for Alzheimer's Disease Detection Using Brain MRI Images. E Hussain, M Hasan, S Z Hassan, T H Azmi, A Rahman, M Z Parvez, Proceedings of the 2020 15th IEEE Conference on Industrial Electronics and Applications (ICIEA). the 2020 15th IEEE Conference on Industrial Electronics and Applications (ICIEA)Kristiansand, Norway, 9Hussain, E.; Hasan, M.; Hassan, S.Z.; Azmi, T.H.; Rahman, A.; Parvez, M.Z. Deep Learning Based Binary Classification for Alzheimer's Disease Detection Using Brain MRI Images. In Proceedings of the 2020 15th IEEE Conference on Industrial Electronics and Applications (ICIEA), Kristiansand, Norway, 9-13 November 2020; pp. 1115-1120.</p>
<p>An Improved ResNet Based on the Adjustable Shortcut Connections. B Li, Y He, 10.1109/ACCESS.2018.2814605IEEE Access. 6Li, B.; He, Y. An Improved ResNet Based on the Adjustable Shortcut Connections. IEEE Access 2018, 6, 18967-18974. [CrossRef]</p>
<p>A transfer convolutional neural network for fault diagnosis based on ResNet-50. L Wen, X Li, L Gao, 10.1007/s00521-019-04097-wNeural Comput. Appl. 32Wen, L.; Li, X.; Gao, L. A transfer convolutional neural network for fault diagnosis based on ResNet-50. Neural Comput. Appl. 2020, 32, 6111-6124. [CrossRef]</p>
<p>A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer's disease. M Liu, F Li, H Yan, K Wang, Y Ma, L Shen, M Xu, 10.1016/j.neuroimage.2019.116459NeuroImage. 208Liu, M.; Li, F.; Yan, H.; Wang, K.; Ma, Y.; Shen, L.; Xu, M. A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer's disease. NeuroImage 2020, 208, 116459. [CrossRef]</p>
<p>Deep residual learning for image recognition. K He, X Zhang, S Ren, J Sun, Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition. the IEEE Conference on Computer Vision and Pattern RecognitionLas Vegas, NV, USAHe, K.; Zhang, X.; Ren, S.; Sun, J. Deep residual learning for image recognition. In Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, Las Vegas, NV, USA, 27-30 June 2016; pp. 770-778.</p>
<p>Forward Stability of ResNet and Its Variants. L Zhang, H Schaeffer, 10.1007/s10851-019-00922-yJ. Math. 2020Zhang, L.; Schaeffer, H. Forward Stability of ResNet and Its Variants. J. Math. Imaging Vis. 2020, 62, 328-351. [CrossRef]</p>
<p>Mish: A self regularized non-monotonic neural activation function. D Misra, arXiv:1908.08681Misra, D. Mish: A self regularized non-monotonic neural activation function. arXiv 2019, arXiv:1908.08681.</p>
<p>Inverse Compositional Spatial Transformer Networks. C H Lin, S Lucey, Proceedings of the 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR). the 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR)Honolulu, HI, USALin, C.H.; Lucey, S. Inverse Compositional Spatial Transformer Networks. In Proceedings of the 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), Honolulu, HI, USA, 21-26 July 2017; pp. 2252-2260.</p>
<p>Spatial transformer networks. M Jaderberg, K Simonyan, A Zisserman, K Kavukcuoglu, Advances in Neural Information Processing Systems. Cambridge, MA, USAMIT PressJaderberg, M.; Simonyan, K.; Zisserman, A.; Kavukcuoglu, K. Spatial transformer networks. In Advances in Neural Information Processing Systems; MIT Press: Cambridge, MA, USA, 2015; pp. 2017-2025.</p>
<p>Non-local Neural Networks. X Wang, R Girshick, A Gupta, K He, Proceedings of the 2018 IEEE/CVF Conference on Computer Vision and Pattern Recognition. the 2018 IEEE/CVF Conference on Computer Vision and Pattern RecognitionSalt Lake City, UT, USAWang, X.; Girshick, R.; Gupta, A.; He, K. Non-local Neural Networks. In Proceedings of the 2018 IEEE/CVF Conference on Computer Vision and Pattern Recognition, Salt Lake City, UT, USA, 18-23 June 2018; pp. 7794-7803.</p>
<p>Attention Is All You Need. A Vaswani, N Shazeer, N Parmar, Advances in Neural Information Processing Systems. Cambridge, MA, USAMIT PressVaswani, A.; Shazeer, N.; Parmar, N. Attention Is All You Need. In Advances in Neural Information Processing Systems; MIT Press: Cambridge, MA, USA, 2017; pp. 5998-6008.</p>
<p>An Automatic Modulation Recognition Method with Low Parameter Estimation Dependence Based on Spatial Transformer Networks. M Li, O Li, G Liu, C Zhang, 10.3390/app9051010Appl. Sci. 9Li, M.; Li, O.; Liu, G.; Zhang, C. An Automatic Modulation Recognition Method with Low Parameter Estimation Dependence Based on Spatial Transformer Networks. Appl. Sci. 2019, 9, 1010. [CrossRef]</p>
<p>Plant recognition using spatial transformer network. A T Syed, S Merugu, V K Koppula, Int. J. Recent Technol. Eng. 7Syed, A.T.; Merugu, S.; Koppula, V.K. Plant recognition using spatial transformer network. Int. J. Recent Technol. Eng. 2019, 7, 334-336.</p>
<p>Deeply-Learned Spatial Alignment for Person Re-Identification. D Chen, P Chen, X Yu, M Cao, T Jia, 10.1109/ACCESS.2019.2945353IEEE Access. 7Chen, D.; Chen, P.; Yu, X.; Cao, M.; Jia, T. Deeply-Learned Spatial Alignment for Person Re-Identification. IEEE Access 2019, 7, 143684-143692. [CrossRef]</p>
<p>Assisted Diagnosis of Alzheimer's Disease Based on Deep Learning and Multimodal Feature Fusion. Y Wang, X Liu, C Yu, 10.1155/2021/6626728Complexity. Wang, Y.; Liu, X.; Yu, C. Assisted Diagnosis of Alzheimer's Disease Based on Deep Learning and Multimodal Feature Fusion. Complexity 2021, 2021, 6626728. [CrossRef]</p>
<p>The Diagnosis of Alzheimer's Disease Based on Enhanced Residual Neutral Network. M Xu, Z Liu, Z Wang, L Sun, Z Liang, Proceedings of the 2019 International Conference on Cyber-Enabled Distributed Computing and Knowledge Discovery (CyberC). the 2019 International Conference on Cyber-Enabled Distributed Computing and Knowledge Discovery (CyberC)Guilin, ChinaXu, M.; Liu, Z.; Wang, Z.; Sun, L.; Liang, Z. The Diagnosis of Alzheimer's Disease Based on Enhanced Residual Neutral Network. In Proceedings of the 2019 International Conference on Cyber-Enabled Distributed Computing and Knowledge Discovery (CyberC), Guilin, China, 17-19 October 2019; pp. 405-411.</p>
<p>An Empirical Study of Spatial Attention Mechanisms in Deep Networks. X Zhu, D Cheng, Z Zhang, S Lin, J Dai, Proceedings of the 2019 IEEE/CVF International Conference on Computer Vision (ICCV). the 2019 IEEE/CVF International Conference on Computer Vision (ICCV)Seoul, KoreaZhu, X.; Cheng, D.; Zhang, Z.; Lin, S.; Dai, J. An Empirical Study of Spatial Attention Mechanisms in Deep Networks. In Proceedings of the 2019 IEEE/CVF International Conference on Computer Vision (ICCV), Seoul, Korea, 27 October-2 November 2019; pp. 6687-6696.</p>
<p>Discovering genomic patterns in SARS-CoV-2 variants. G D&apos;angelo, F Palmieri, 10.1002/int.22268Int. J. Intell. Syst. 2020D'Angelo, G.; Palmieri, F. Discovering genomic patterns in SARS-CoV-2 variants. Int. J. Intell. Syst. 2020, 35, 1680-1698. [CrossRef]</p>            </div>
        </div>

    </div>
</body>
</html>